Betta Pharmaceuticals: 2025 Sustainability Report
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Bebe Dada Pharmaceutical Co., Ltd. || 22002255 Annual Cocoa Sustainable Development Development Report
Trustworthy management, protecting health, green protection, working together to achieve long-term good deeds
Table of contents About this report
About this report 02 Chairman’s speech 04 Introduction to the report
Statement of the Board of Directors 03 About Us 05 This report is the first sustainability report issued by Betta Pharmaceuticals Co., Ltd. It aims to disclose the company's management, practices and performance in sustainable development (environmental, social and corporate governance, hereinafter referred to as ESG) and respond to the expectations and concerns of various stakeholders.
Organization scope
01 04
This report covers the economic, social, environmental and corporate governance performance of Betta Pharmaceuticals Co., Ltd. and its subsidiaries. For ease of presentation and reading, this
Steady governance, trustworthy management, people-oriented, working together to make progress
In the report, unless the context otherwise requires, Betta Pharmaceuticals Co., Ltd. and its subsidiaries are represented by "Betta Pharmaceuticals", "the Company", "the Company" or "we".
Corporate Governance 08 Staff Employment 42
ESG Governance 09 Protection of Employee Rights and Interests 43 Time Range
Risk Compliance Management 11 Employee Training and Development 47 From January 1, 2025 to December 31, 2025, in order to maintain the continuity and integrity of information, some content exceeds the above scope.
Business Ethics and Anti-Corruption 12 Occupational Health and Safety Production 49
Compilation basis
02 05
• "Shenzhen Stock Exchange Self-Regulation Guidelines for Listed Companies No. 17 - Sustainability Report (Trial)"
• United Nations 2030 Agenda for Sustainable Development (UN SDGs)
• Appendix C2 “Environmental Protection” of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
R&D and Innovation 14 Public Welfare Party Building 52 • "Disclosure Recommendations of the Task Force on Climate-related Financial Information Disclosure (TCFD)"
Environmental, Social and Governance Reporting Code
Privacy protection and information security 19
Appendix 53
Product Quality and Safety 20
Data description
Clinical Trials and Subject Safety 25 Appendix I Key Performance Table 53
The data used in this report are all derived from the company's internal official documents, internal statistics and relevant public materials. Among them, key financial performance data mainly come from "Betta Pharmaceuticals Sustainable Supply Chain 26 Appendix II Shenzhen Stock Exchange and Hong Kong Stock Exchange ESG Guidelines Index 56
Co., Ltd. 2025 Annual Report". Unless otherwise stated, the amounts shown in this report are in RMB. The Board of Directors is responsible for the truthfulness, accuracy Responsible Marketing 28 Appendix III Feedback Form 60 and completeness of the report content.
03 How to obtain the report
Low carbon operation, green escort
This report is available in Chinese and English versions for readers' reference. If there is any discrepancy, the Chinese version shall prevail. It can be viewed and downloaded from the company's website (https://www.bettapharma.com/).
Environmental Management 30
Addressing climate change 34
Contact us
Energy use 36
We look forward to valuable suggestions from all stakeholders. If you have questions or suggestions about the sustainable development work of Betta Pharmaceuticals or the content of this report, please feel free to contact us through the following methods Resource Management 37
Contact:
Emissions Management 38
Biodiversity 40 Tel: 0571-89265665 Email: [email protected]
01 02 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolence and mutual support
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Statement of the Board of Directors Message from the Chairman
The Company complies with the relevant regulatory requirements of the Shenzhen Stock Exchange and the "Self-Regulatory Guidelines for Listed Companies of the Shenzhen Stock Exchange No. 17 - Sustainability Report. The biopharmaceutical industry is a strategic emerging industry related to the national economy and people's livelihood. It is an emerging pillar industry that the country is accelerating to build during the 15th Five-Year Plan, and it is also an important support for protecting the people (Trial)". It also refers to the "Environmental, Social and Governance Reporting Code" of the Hong Kong Stock Exchange, and continues to strengthen the board of directors' supervision and participation in ESG matters, which is an important support for promoting healthy and high-quality development. In 2025, under the dual opportunities of the global wave of pharmaceutical innovation and domestic industrial upgrading, Betta Pharmaceuticals will firmly adhere to its mission of sustainable development, fulfill its social responsibilities as a pharmaceutical company, and contribute to the innovation, compliance and high-quality development of China's pharmaceutical industry. We will further advance the listing layout, continue to deeply integrate ESG concepts into the company's strategic decision-making and the entire process of business development, and adhere to the principle of "making good medicine so that people can live better."
Our mission is to drive development with innovation, fulfill our responsibilities with responsibility, and move forward steadily on the road of protecting public life and health and promoting high-quality development of the industry. The board of directors deeply realizes that integrating ESG issues into the entire process of drug research and development, production operations, supply chain management and clinical application is critical to the company's long-term stable development.
Focusing on the three core dimensions of ESG, we focus on promoting the following work:
It is important and complies with the ESG regulatory disclosure requirements of the Shenzhen and Hong Kong exchanges. As the highest decision-making body on ESG matters, the board of directors bears the ultimate responsibility for ESG matters.
Supervise key sustainable development issues such as drug quality and safety, R&D compliance, assess and determine the scope of ESG risks, review and optimize ESG management strategies, and identify management and control
To deal with major ESG risks, we must adhere to the bottom line of compliance, practice pharmaceutical corporate social responsibilities, and ensure compliance with ESG compliance requirements for listings in Shenzhen and Hong Kong. In terms of governance, we always adhere to the bottom line of compliance operations and regard standardized governance as the foundation of ESG work. The company strictly follows the relevant rules of the Shenzhen Stock Exchange and the Hong Kong Stock Exchange, continues to improve the corporate governance structure, strengthens internal control and compliance management, and builds a multi-level audit supervision defense line to ensure stable corporate compliance. Relying on a complete ESG management structure, the company promotes the implementation of ESG work in an orderly manner and continues to improve ESG management capabilities and performance. In daily operations, the company will manage ESG
Operation and adaptation dual regulatory needs; at the same time, ESG requirements are deeply integrated into the entire process of strategic decision-making and operation management, and a scientific governance system is used to ensure the deep integration of corporate high-quality concepts and development strategies. Combined with the characteristics of the pharmaceutical industry and the characteristics of innovative drug research and development, the ESG management system is improved, and R&D compliance and drug quality control are optimized.
to achieve substantial development and provide solid protection for the rights and interests of shareholders and stakeholders.
and other measures to promote green production and supply chain ESG control, strengthen compliance culture and employee ESG training, normalize and standardize ESG work, and take into account corporate innovation
New development and social and environmental values help build a healthy China. In the environmental dimension, we are based on the characteristics of the pharmaceutical industry, practice the concept of green development, and promote the green transformation of the production process. Relying on measures related to energy conservation and carbon reduction in the park, we continue to optimize production processes, promote a win-win situation of energy conservation and carbon reduction and optimization of operating costs, integrate the concept of green development throughout the entire production process, and effectively implement environmental protection.
Environmental responsibility, support ecological protection, and achieve coordinated advancement of corporate development and environmental sustainability.
Optimize ESG management strategies. This report discloses in detail the company's ESG work progress and results in 2025, truly reflects the practical results, and ensures that the content contains no false records,
Misleading statements or material omissions comply with the ESG information disclosure specifications of regulatory agencies and were reviewed and approved by the board of directors on April 21, 2026. In the social dimension, we have always kept in mind the original intention of protecting public life and health, based on our industry advantages, and fulfilled our social responsibilities in multiple dimensions and in an all-round way. In terms of innovation and empowerment, we continue to strengthen the research and development of new drugs. Ensartinib has been prescribed for the first time in the United States and Macau, China, and has officially entered clinical application to benefit patients. The independently developed new drug Teresicil has been approved for marketing, providing new treatment options for breast cancer patients. In terms of employee care, we always regard employees as the core force of corporate development and strictly protect employees. We protect the legitimate rights and interests of employees, improve the salary, benefits and incentive system, build diversified career development channels, and create a good atmosphere of respecting talents, caring for employees, and collaborative growth; in terms of people's livelihood and public welfare, we actively provide advice and suggestions on topics such as medical insurance optimization and rare disease medication, to help improve the health literacy of the people, and deeply integrate responsibility and responsibility into the blood of corporate development.
Standing at a new starting point for development, Betta Pharmaceuticals will continue to be guided by the ESG concept, deeply implement the concept of "connecting innovation with demand, and developing with responsibility". On the basis of consolidating the results of work in the three major dimensions of governance, environment, and society, Betta Pharmaceuticals will continue to deepen independent innovation, optimize the ESG management system, promote the export of innovative drug results, and allow Chinese innovative drugs to serve the global market. At the same time, the company will continue to exert its influence in the industry, link up the forces of all parties, focus on medical innovation, people's livelihood security, ecological protection and other fields to actively provide suggestions and promote high-quality development of the industry; always adhere to the original intention and mission of a pharmaceutical company, take into account economic value, social value and environmental value, work hand in hand with stakeholders, and contribute to promoting the innovative development of China's biopharmaceutical industry and protecting human life and health.
03 04
Steady and sound governance, quality-oriented, low-carbon operations, people-oriented, benevolent and working together, Beida Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Xinxinyiyi operates, protects health, and protects the green environment. Hand in hand, we make progress together. Good deeds go far.
About us
Company Profile
Betta Pharmaceuticals (300558.SZ) was founded in 2003 and is headquartered in Hangzhou, Zhejiang. It is a high-tech pharmaceutical company founded by a team of high-level overseas returnees. As a Chinese anti-tumor
A pioneer in the field of innovative tumor drug research and development, the company independently developed China's first small molecule targeted anti-cancer drug icotinib hydrochloride tablets (Kemena®), filling the domestic gap and breaking the industry.
It has won the first prize of National Science and Technology Progress Award, China Patent Gold Award, China Industry Award and other honors. Since then, the company has successfully developed and launched ensartinib hydrochloride capsules (Bemena
®), befutinib mesylate capsules (Semena®), voronib tablets (Femena®) and other Class 1 new drugs, continue to meet the health needs of the people. Betta Pharmaceuticals adheres to the principle of "self-
The four carriages of "main R&D, strategic cooperation, marketing and innovation ecosystem" have coordinated development, continue to strengthen the research and development of new drugs, and are committed to becoming a multinational pharmaceutical company headquartered in China.
company milestones
• A team of high-level talents who have returned from overseas • Icotinib was approved for listing • The company was listed on the Shenzhen Stock Exchange • Ensartinib was approved for listing • The company was awarded the National Employee Career Award • Ensartinib was approved by the FDA and was established in Hangzhou, Zhejiang as an advanced unit for moral construction. Listed in the United States
• Icotinib was approved by my country’s industrial field • Ensartinib’s clinical research was rated as “China’s
The highest award - China Industry Award "Top Ten Original Research in the Field of Oncology" • The company was rated as National Technological Innovation • The company was rated as High Quality in Zhejiang Province
Demonstration enterprise and development leading enterprise
• The company was rated as “National Enterprise Technology Center”
2003 2020
2016 2024
2011 2022
2008 2021
2019 2025
2015 2023
• Teresicil tartrate (commeta
• Befortinib and voronib (Beforatinib®) were approved for marketing
• Bevacizumab injection (bevacizumab
Listed in batches
• Icotinib R&D and industrialization Antin®) was approved for marketing, research • The company entered the 2025 China for the first time
• The company was recognized for the first time as one of the national scientific and technological advances. • The company was rated as one of the "Lancet" sub-journals. • The company won the first prize of the National High-tech Enterprise with R&D investment of 500 by private enterprises in China Biomedicine. The national intellectual property demonstration enterprise EClinicalMedicine published the special prize of the high-value patent competition. Home list
05 06
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Bebe Dada Pharmaceutical Co., Ltd. || 22002255 Annual Cocoa Sustainable Development Development Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
corporate governance
Betta Pharmaceuticals strictly abides by the "Company Law of the People's Republic of China", "Securities Law of the People's Republic of China", "Shenzhen Stock Exchange Growth Enterprise Market Stock Listing Rules", "Securities Listing Rules of the Stock Exchange of Hong Kong Limited" and other laws, regulations and listing rules of the place where it operates. Based on the development of the company's innovative drug research and development, production and sales business, it establishes and continues to improve the corporate governance structure, further standardizes R&D management, production operations, marketing and compliance control processes, and enhances the standardization and professionalization of corporate governance.
To ensure fairness and protect the legitimate rights and interests of shareholders, patients, employees and other stakeholders.
Board composition
The company's board of directors is responsible to all shareholders. Its core responsibilities include formulating medium- and long-term development strategies,
2025
Innovative drug R&D and operation management goals, coordinating the entire chain of drug R&D, production and sales
Supervise the implementation of strategic goals and the implementation efficiency of management's various business strategies. The company held multiple board meetings, and all directors strictly performed their duties. In order to strengthen special supervision and professional guidance in key areas, the board of directors has established a strategy committee,
Audit Committee, Nomination Committee, Remuneration and Appraisal Committee, and Sustainability Committee have a meeting attendance rate of %
There are five professional committees, each of which is based on the company's articles of association and rules of procedure.
Perform responsibilities in the field, provide necessary professional support and supervision for the scientific decision-making of the board of directors, and ensure that all major decisions are fully reviewed and voted on in a standardized manner.
to ensure that governance processes are compliant and decision-making is efficient.
Board Diversity
The board of directors of Betta Pharmaceuticals consists of 12 members, including 7 non-independent directors, 1 employee director and 4 independent non-executive directors. The board of directors has a reasonable structure and clear division of labor, forming an effective checks and balances mechanism. The company provides sufficient guarantee for independent non-executive directors to effectively perform independent supervision and verification functions, ensuring that they can be independent from management and fully play their role in supervision and sound governance 01. Independent non-executive directors account for 33.3% of the total number of directors on the board of directors, which meet the listing regulatory requirements of Shenzhen and Hong Kong. They play a key balancing role in the company's major R&D decisions, risk management and control, compliance operations, medical ethics, etc., and provide independent and objective professional insights for the board of directors' decision-making.
The company is well aware that the members of the board of directors have diverse backgrounds, rich experience in the pharmaceutical industry and cross-field professional capabilities, which are important supports for the company to achieve breakthroughs in innovative drug research and development and sustainable development, and help the company to carry out decision-making and long-term development planning comprehensively and objectively. In order to continue to promote the diversification of the board of directors, comprehensive consideration will be given to the nomination of director candidates.
Trustworthy management
Multiple factors such as gender, age, cultural and educational background, professional field, pharmaceutical industry experience, R&D management skills, compliance management capabilities and service period. The current board of directors includes 3 female directors, accounting for 25%.
Information Disclosure and Investor Relations Management
Contributing to SDGs Responsible governance is an important foundation for corporate sustainable development. Betta Pharmaceuticals actively implements the "Information Disclosure Management System", establishes the Securities Department as a full-time information disclosure department, and equips a professional compliance team. It strictly abides by the "Sustainable Development Concept of Securities Banks of the People's Republic of China, continues to improve the ESG governance structure, and always attaches great importance to the interests of the public." ensure the authenticity, accuracy, completeness and timeliness of the disclosed information. The company always adheres to the principle of fair disclosure, ensures open and fair information disclosure, prevents the leakage of inside information, adheres to the corporate culture of compliance, creates long-term economic value and social value for the company, and effectively protects the equal right to know of all investors. The company uses official channels such as Juchao Information Network and Securities Times as the core information disclosure carrier to lay the foundation for timely delivery of the company's operating dynamics to the market. and performance to ensure that information disclosure channels are compliant and the content is true, accurate and complete.
Betta Pharmaceuticals has formulated the "Investor Relations Management System" and designated the secretary of the board of directors to be responsible for organizing and coordinating investor relations management work. The Securities Department is the functional department for investor relations management to carry out investor communication and other work on a regular basis. The company has established diversified investor communication channels. The official website has a special column for investor relations management. It also builds regular and efficient communication bridges through shareholders' meetings, performance briefings, reception and exchanges, Shenzhen Stock Exchange interactive platform, investor hotlines and emails, WeChat public accounts and other channels to interact smoothly with investors, respond to investor demands, and ensure equal access to information for small and medium-sized shareholders.
As an important way for companies to give back to shareholders, cash dividends are a key link between shareholders' interests and company value. Since its listing, the company has continued to implement the profit distribution policy to ensure shareholder returns, share the results of business development with all shareholders through practical actions, and effectively enhance the sense of gain for investors.
07 08
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
ESG governance issues of dual importance
This year, Beida Pharmaceutical carried out ESG dual importance analysis, comprehensively considering the financial impact of ESG issues on the company and the impact of the company's performance on the corresponding issues on the economy, society and environment. Beida Pharmaceutical has gradually integrated ESG factors into business and strategic decisions, built a complete ESG governance system, identified key ESG issues through dual importance analysis, and established regular
environmental impact. By conducting stakeholder surveys, we collected more than 190 survey questionnaires and systematically evaluated the impact of ESG issues on stakeholders at the environmental, social and governance levels. We established a stakeholder communication mechanism to respond to the concerns of all parties and promote the company's sustainable development.
At the same time, we analyze the financial impact of important issues and evaluate the financial importance of ESG issues. This year, the company identified 23 ESG issues that have a substantial impact on the company's operations. After confirming the dual importance assessment results of the issues, the company formed a dual importance matrix and used the matrix results as an important consideration in future development planning.
ESG governance system
〇 Betta Pharmaceuticals Dual Importance Matrix
Environment Social Corporate Governance
An effective ESG management system is an important support for a company to achieve its sustainable development goals. Betta Pharmaceuticals has built a three-level ESG management framework covering the decision-making level, management level and execution level.
structure, clarify management concepts, principles, strategies and division of responsibilities, and continue to improve supporting systems to continuously improve ESG management capabilities and overall performance.
Board of Directors (Decision-Making Level) Sustainability Committee (Management) Various Departments of the Company
Product quality and safety
Clinical trials and subject safety
The Board of Directors and the Sustainability Committee under it are responsible for formulating the company's ESG short, medium and long-term policies.
Emissions management
The company's top management and decision-making authority for ESG work. ESG short, medium and long-term strategies and plans, review period strategies and plans, participate in analysis, evaluation and
Employee compensation and benefits
structure. The main responsibilities of the Sustainability Committee are to coordinate ESG-related policies and important internal management data to promote the implementation, identification and evaluation of ESG goals.
Review the company's sustainable development and ESG-related regulations, and provide decision-making suggestions for ESG-related matters. Occupational health and safety, innovation and R&D, plan goals, performance, annual sustainable development and resource support, ensure ESG goals and policies, and collect and submit ESG-related indicators for the department. Employee rights and equal employment.
Intellectual property protection
/ESG reporting and other major matters, guide and implement them, lead the ESG working group to implement sustainable evidence, participate in ESG-related training work, and report regularly
Supervise the company's sustainable development and ESG work implementation policies and strategies, and regularly report to the board of directors on the progress of the department's ESG work. water resources utilization
Compliance management
performance and make recommendations to the Board of Directors. report. Anti-corruption and business ethics Inclusive healthcare Energy use Employee development and training
Risk Management Corporate Governance Circular Economy Biodiversity Protection Addressing Climate Change
Community and Charity Responsible Marketing
Stakeholder communication
sustainable supply chain
Betta Pharmaceuticals attaches great importance to the expectations and demands of stakeholders, understands the opinions and suggestions of management and employees through multiple channels, and regularly reports to the government/regulatory agencies, shareholders/investors
Communicate and communicate with stakeholders such as investors, customers/patients, community members, suppliers/partners, etc., and actively respond to the concerns of all parties.
Environmental issues Social issues Corporate governance issues
• Risk compliance management • Product quality and safety • Compliance information disclosure • Pay taxes in accordance with the law
Government/Regulatory Agencies • Emissions Management • Product Quality and Safety • Compliance Operations
• Business ethics • Environmental management • Comply with business ethics • Ensure environmental compliance management
• Water Utilization • Innovation and R&D • Anti-Corruption and Business Ethics
• Energy use • Clinical trials and subject safety • Risk management
• R&D and innovation • Actively engage in R&D and innovation • Hold regular shareholder meetings
Shareholders/Investors • Addressing climate change • Intellectual property protection • Corporate governance
• Compliance and Risk Management • Compliance Information Disclosure
• Biodiversity conservation • Occupational health and safety
Customers/Patients • Product quality and safety • Information security and privacy protection • Strengthening quality management • Strengthening information security management • Circular economy • Employee compensation and benefits
• Employee rights and equal employment
• Employee rights and benefits • Employee training and development • Smooth democratic communication • Strengthening health and safety management
Staff • Staff development and training
• Occupational health and safety • Improve employee welfare • Optimize employee development channels
• Responsible marketing
• Inclusive medical care
• Environmental management • Charity • Improve environmental management • Participate in public welfare activities
Community Public • Sustainable Supply Chain
• Emission management • Improve information communication channels
• Information security and privacy protection
Suppliers/industry partners • R&D and innovation • Supply chain management • Regular communication • Collaboration to create sustainable development • Community and public welfare
Gravity influences sex
financial importance
Stakeholders’ expectations and demands Communication and response
09 10
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Risk Compliance Management Business Ethics and Anti-Corruption
Betta Pharmaceuticals has always regarded a sound governance structure and comprehensive compliance management as the cornerstone of the company's sustainable development. Through systematic internal audits, compliance education for all employees and the entire chain, Betta Pharmaceuticals is committed to operating with integrity, ethics and compliance, and abiding by all laws and regulations related to anti-corruption and anti-bribery risk management in the jurisdictions where it operates, to provide guarantee for the stable and efficient operation of the business. Regulations and normative documents. The company has formulated systems and standards such as the Anti-Corruption and Anti-Bribery Policy and the Code of Ethical Conduct for Employees to standardize the professional conduct of all employees of the company.
To prevent corruption, money laundering and other risks. During the reporting period, the Company did not have any corruption litigation cases.
risk management
We focus on building a business ethics culture and conduct regular business ethics training. We require new employees to complete business ethics training and assessment during the probation period. Those who fail will not pass the probation period evaluation.
Betta Pharmaceuticals attaches great importance to risk management and control, formulates the "Comprehensive Risk Management Measures" in accordance with national laws and regulations, improves the comprehensive risk management system, and integrates environmental protection and safety management.
Environmental and social-related factors such as management and business ethics should be incorporated into operational risk management. As the core decision-making body of risk management, the board of directors is responsible for planning the risk control system and proposing risk
Management objectives and requirements, review relevant systems and major risk disposal plans; the Strategy Committee, in accordance with the requirements of the Board of Directors, formulates risk control plans and implements optimization to handle major risks
current year
and guide the risk management work of subordinate enterprises; as the risk management functional department, the Internal Control Affairs Department is responsible for system construction, system formulation, risk assessment, training and assessment, and cultural construction.
Established and reported to the management; the Internal Control Affairs Department, as the supervisory department, is responsible for supervising and evaluating comprehensive risk management work to ensure that the system is compliant and effective. We participated in business ethics training in total. The total business ethics training hours were Training coverage rate
The company has established a risk information collection and accumulation mechanism. Risk information covers macroeconomics, policies and regulations, market conditions, technological innovation, finance, human resources, management, information reporting, etc. 1,817 1,122 100
Person-time %
For content related to risk management, combined with the actual operation and management, organize various departments to carry out risk identification, describe and classify various specific risks according to unified assessment standards, and evaluate key risks.
A risk management list is formed for large and important risks, and the focus and management priorities are clarified through comparative evaluation to improve the pertinence of management and control.
The company has established a business ethics compliance due diligence system covering the entire life cycle of suppliers and dealers, covering standard screening, document review, background investigation and hierarchical approval, etc.
Internal control and compliance management
process, and implement “one-vote veto” for compliance risks. The system assessment uses methods such as document review, risk rating and information cross-verification. All important partners must pass the above due diligence process and accept the company's continuous compliance supervision. We have set up relevant clauses on anti-corruption and anti-commercial bribery requirements in our contracts with suppliers and dealers to ensure that we continue to improve our compliance management organizational system. To ensure continued compliance operations, the company has established a multi-level audit supervision line of defense. The audit committee under the board of directors is responsible for supervising the business ethics management of suppliers and dealers.
Evaluate the effectiveness of the internal audit function within the company's risk management system. The company regularly carries out internal audit work every year, and the audit scope fully covers all departments and subordinate companies of the company.
Betta Pharmaceuticals encourages employees to make real-name reports on various violations of laws and regulations. If any unit or individual discovers a company that violates or may violate national laws, regulations and company-related policies, audit types include daily routine audits, special audits, resignation audits, etc., through regular audits, risks in each business link are accurately identified, and relevant departments are urged to implement prevention and control
Yes, reports can be made through the Company Compliance Hotline. All reported concerns and related information will be truthfully recorded and fed back, and the company will quickly investigate and deal with the reported situation. Company commitment measures.
Personnel who raise concerns, report violations or provide information during investigations will be protected and their identities and related information will be kept strictly confidential. Any individual is strictly prohibited from retaliating against whistleblowers. Once discovered, the company will impose severe penalties in accordance with laws and regulations.
During the reporting period
Betta Pharmaceuticals Complaint Feedback Channel
The company completed regular audits, special audits and resignation audits, adhered to a problem-oriented approach and put forward management suggestions
12 8 13
item item item
Tel: 0571-86176096 Email: [email protected]
Promote the rectification of problems found in audits, form an effective closed loop of supervision, and continuously improve the quality of internal control
〇 Quantitative indicators
The company incorporates compliance culture into its development strategy and corporate culture construction, incorporates employee compliance training into the company's training plan, and guides employees to enhance risk awareness and abide by codes of conduct and ethics.
Key Indicators Unit 2025
Moral norms.
Number of closed corruption litigation cases 0
Total number of directors participating in anti-corruption training during the reporting period Person 6
The average number of hours directors have participated in anti-corruption training hours 2 The company carries out various compliance trainings covering more than
Anti-corruption training
Total number of employees participating in anti-corruption training 3,169
21 3,000
Visitors
Average total training hours for employees to participate in anti-corruption training hours 1.08
11 12 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolence and mutual support
Bebe Dada Pharmaceutical Co., Ltd. || 22002255 Annual Cocoa Sustainable Development Development Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
R&D and Innovation
With the research and development of innovative drugs with independent intellectual property rights as its core, Betta Pharmaceuticals is committed to realizing innovation for the people, benefiting the people with science and technology through new drug research and development, and helping to improve people's health and well-being.
Governance 〇 Betta Pharmaceuticals R&D Governance Structure
Responsible for evaluating preclinical and clinical research projects, managing the company's focus on unmet clinical needs, and steadily advancing clinical research on innovative drugs. Public New Drug Research and Development Committee manages and makes decisions.
The company has established a new drug research and development committee to review the scientific background and establishment of new drug research and development projects.
Evaluate based on project basis, exploratory research results and other dimensions; at the same time formulate and implement Responsible for the promotion of new drug research and development projects, maximizing the research and development results of the institute
power and reduce R&D risks.
The "Full-Cycle Management Measures for New Drug Projects" regulates the company's entire clinical research process.
strategy
As a pioneer in the field of innovative anti-tumor drug research and development, the company's successful new drug research and development and commercialization experience has laid a solid foundation for the company's continued innovation and development. Through a model that combines independent research and development with strategic cooperation, the company has built a comprehensive drug pipeline covering key lung cancer targets, further consolidating its leading position in the field of innovative targeted lung cancer treatments, and gradually deploying multiple subdivisions such as breast cancer, kidney cancer, hematology, and ophthalmology to broaden its business development boundaries.
Through systematic risk identification and assessment procedures, the company conducts comprehensive research and judgment on potential impacts, risks and opportunities under R&D and innovation, and based on this, develops targeted management strategies to ensure the compliance and sustainability of operational activities.
Quality first 02
Type Specific description Financial impact Countermeasures
New drug R&D and launch risks: There is high investment in R&D of innovative drugs. Sunk costs of R&D investment: The huge amount of R&D funds that have been invested. 1. Relying on a mature project management system to optimize the R&D pipeline. The characteristics of long cycle and low success rate, the risk cannot be recovered throughout clinical development, which may lead to a sharp decline in profits for the current period; resource allocation, through dynamic adjustment of R&D strategies and strengthening mileage risks. Development cycle, clinical trial design plan, differences in patient groups. Launch delay losses: product launch time is delayed, missed market Monumental progress control, construction coverage, target selection, clinical application and health protection, etc. may lead to data not meeting standards and leading to clinical failure. A full-cycle management system that displays expected sales revenue and market share during the market window period.
Pharmaceutical companies generally adopt fast-following strategies to accelerate target coverage.
In this case, the research progress will also affect the market competitive position.
Risks of loss of core technical personnel: Core talents are the company's products. Project interruption and delay costs: The loss of key personnel leads to research and development project stagnation or rework, which increases additional costs and delays production, integrates short-term and long-term incentives, and creates competitive factors and an important foundation. The current competition for talents in the pharmaceutical industry is to launch products on the market; a competitive salary system;
continues to intensify. If the company loses core talents, it may
Loss of intellectual assets and replacement costs: core technology and business 2. Cultivating a corporate culture with Betta characteristics and strengthening employees can cause delays in new drug research and development, leakage of business secrets, and impact on projects.
Contributing to SDGs, Betta Pharmaceuticals adheres to the mission of "making good medicines so that people can live better lives" to create risk-based project progress, bring secrets to the company's product development and periodic income, train secret personnel, and weaken weak personnel. Re-recruitment and return 3. A sense of belonging and aggregation of potential;
Talent development planning and promotion of talents will have adverse effects.
New R&D serves as a sustainable driving force, deepens the collaboration between industry, academia and research, and steadily promotes the echelon construction of innovative drug management, allowing core employees to work with the company on R&D and intellectual property layout; taking quality control as the bottom line of safety, establishing a company that is consistent with common development and shared benefits;
Dynamically introduce high-end and key talents to enrich the R&D team; implement domestic and foreign standard quality management systems to realize the entire life cycle from drug R&D to production.
Establish a complete confidentiality and intellectual property protection system. Cycle quality is controllable; taking the entire value chain as an extension of responsibility to build sustainable supply
Clinical demand and market expansion opportunities: Lung cancer is a malignant tumor in China Core product revenue growth and life cycle extension: The company is 1. Adhering to the clinical demand orientation, based on innovation, strengthening the research chain, standardizing clinical research and marketing services, and effectively protecting the rights and interests of patients and the public
The number one cause of cancer morbidity and death and the number one cancer in the world. The continued layout of core lung cancer targets will promote the development team building of existing products;
health. disease. The company is committed to providing multiple solutions for the treatment of lung cancer patients to increase market penetration. At the same time, through the expansion of new indications, 2. Combining market demand and clinical value, accelerating clinical cases, through independent research and development and strategic cooperation, extending the product life cycle around EGFR and combination therapy development, stabilizing and expanding
The progress of research projects, especially the acceleration of early clinical research on targets such as ALK and RAS, and the in-depth deployment of lung cancer treatment products, while increasing core sales revenue;
Opportunities: Entering the critical phase of clinical trials and achieving transformational applications;
Advance research and development in other mutation areas.
Increasing market segments: Expanding into other high-potential mutation fields, 3. Strengthening contact and cooperation with outstanding domestic and foreign companies, opening new market segments around cancer, forming core targets and emerging disease treatment frontiers, introducing more high-quality projects, consolidating the multi-round growth curve of target targets, reducing the leading position of single products in the field of lung cancer, and actively expanding diversification.
Lai, improve income stability. chemical treatments.
13 14
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Impact, Risk and Opportunity Management In addition, the company fully taps the clinical potential of its products and actively expands different indications of the same product to maximize product value and meet the needs of more patients.
Voronib Ensatinib
Focusing on various risks and development opportunities throughout the R&D process, the company has established a management system covering the entire R&D life cycle, continues to refine the management specifications at each stage, deepens R&D innovation, and continuously
Continuously improve R&D efficiency and achievement transformation capabilities. At the same time, the company has fully integrated the research and development process into daily risk management, regularly conducts comprehensive risk assessments, and standardizes the promotion of risk awareness. Voronib has introduced high-efficiency, oral, small-molecule dual-specific kinase inhibitor ensartinib for the company. Data on post-operative adjuvant treatment of ensartinib are classified, evaluated and responded to by the European Society of Medical Oncology in 2025 (see the "Risk Compliance Management" chapter for details). The preparation, targeting human vascular endothelial growth factor receptor (VEGFR) and platelet derivatives (ESMO), was first disclosed at the annual meeting of ensartinib and was disease-free for 2 years after adjuvant treatment.
growth factor receptor (PDGFR). In June 2023, voronib was approved for marketing, with a survival (DFS) rate of 86.4% and a 2-year disease-free survival hazard ratio (HR) for the product development pipeline for the treatment of advanced renal cell carcinoma (RCC); at the same time, through external cooperation, the wetness 0.20 was promoted, and the risk of recurrence was reduced by 80%, significantly reducing the possibility of disease recurrence. Age-related macular degeneration (wAMD) and diabetic retinopathy (DME), etc.
Expansion of ophthalmic indications.
Through independent research and development and strategic cooperation, the company has focused on new drug pipelines covering multiple treatment fields such as lung cancer, breast cancer, and solid tumors, forming a "rhythmic clinical advancement and layered pipeline layout".
times” good pattern.
R&D Platform
10 5
As of now, the company's R&D pipeline covers the remaining drug varieties, including innovative drugs, and 4 products have been included. The company adheres to the patient-centered, clinical value-oriented R&D philosophy and has established
March 2026
9 2 2 National Medical Insurance Drug Catalog
Among them, 2 products have been successfully approved for marketing, 2 biosimilar drugs and 3 cooperative distribution products have established a leading new drug research and development system with Betta Research Institute as the core. As of the end of the reporting period,
The company has 298 R&D personnel, including 34 Ph.D.
Internationally renowned experts with drug research and development experience accounted for 16.69% of the total number. reporting period
〇 Beida Pharmaceutical Product Pipeline Diagram
During the year, the company's R&D investment reached 573.5002 million yuan, accounting for 15.89% of operating income. National Postdoctoral Research Workstation Zhejiang Postdoctoral Workstation
In addition, the company has established a national-level postdoctoral research workstation. The postdoctoral mobile station serves as an important platform for the company to cultivate innovative talents. The company jointly carries out postdoctoral recruitment and training with well-known universities. As of the end of the reporting period, a total of 35 postdoctoral students have been recruited, and 28 have successfully graduated. The postdoctoral mobile station has submitted a total of 29 invention patents, published 18 papers, and participated in 3 key R&D plans of Zhejiang Province.
The company continues to increase its resource investment in key projects and unmet clinical needs, while actively introducing cutting-edge technologies and continuing to explore new targets and new treatment areas. We have established a multi-modal discovery engine that combines four proprietary technology platforms, including advanced small molecule targeted drug platform, GlueOnX (molecular glue platform), DegradoX (protein degradation targeted chimera (PROTAC) degrader platform) and AlbuVive (albumin therapy platform), to promote the research of innovative and clinically urgent new drugs.
innovation ecosystem
In order to achieve complementary advantages and coordinated development, and promote the interaction and exchange of talents, projects, information and funds, the company relies on Betta Industrial Fund and Betta Dream Factory to promote the acceleration of incubation, investment and achievement transformation, and closely connect top scientific talents, emerging technologies and unmet clinical needs. Through equity investment and strategic incubation, we have established in-depth cooperation with partners, achieved rapid transformation of laboratory-stage innovations into clinical-stage assets, and lowered the threshold and opportunity cost of biopharmaceutical entrepreneurship.
Industry exchange
The company actively participates in industry exchange platforms such as international seminars and industry summits, continues to promote the in-depth integration of industry, academia and research, and effectively integrates high-quality industry resources. The company has led the formulation of 12 quality standards for Class 1 new drugs in 6 countries. During the reporting period, the company obtained 2 new standards approved by the State Food and Drug Administration.
Four research results of Betta Pharmaceuticals were unveiled at the 2025 AACR Annual Meeting
April 2025, BPI-572270, BPI-585725, BK-001 of Betta Pharmaceuticals
(VM-001), MCLA-129 and other four research results will be unveiled on the 116th of 2025
The annual meeting of the American Association for Cancer Research (AACR) reflects the company’s insistence on independence
Combining R&D with global cooperation to accelerate the development and clinical development of innovative anti-tumor drugs
bed transformation and continue to provide patients with more effective treatment options.
Betta Pharmaceuticals gave an oral report at the AACR Annual Meeting
15 16
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
〇 Betta Pharmaceuticals Intellectual Property Risk Prevention and Control Process
Betta Pharmaceuticals’ ensartinib and icotinib research results were unveiled at the 2025 ASCO Annual Meeting
- Pre-project search: Conduct existing technology search and preliminary FTO analysis to identify potential risks and innovation space.
May 30-June 3, 2025, senior vice president and global sales president of the company
Wan Jiang and Professor Mao Li, President of R&D and Chief Medical Officer, participated in the 2025 U.S. Clinical
- Avoidance design during R&D: Guide the R&D path based on the search results, and carry out avoidance design or patent layout planning.
Annual Meeting of the Society of Oncology (ASCO). Betta Pharmaceuticals product ensartinib QEELIN research
The results of the research and icotinib CORIN were presented at the annual meeting in the form of posters. Two
- Apply for protection after production. Apply for high-quality patents on innovative results in a timely manner to build a rights barrier.
The research reflects the company’s continuous innovation capabilities and solid clinical experience in the field of lung cancer treatment.
Clinical trial data accumulation.
Betta Pharmaceuticals will appear at the 2025 ASCO Annual Meeting 4. Pre-transaction or pre-market risk review Before the product is put on the market, conduct a comprehensive FTO final review and formulate a risk plan.
- Emergency response to infringement incidents: Establish an infringement monitoring and rapid response mechanism. Once suspected infringement or infringement is discovered, an emergency plan will be launched immediately and rights protection or response measures will be taken in accordance with the law.
To deepen school-enterprise collaborative innovation, Betta Pharmaceuticals has reached a cooperation with West Lake University. In order to continuously strengthen the intellectual property protection awareness of company employees and improve the intellectual property protection capabilities of relevant personnel, we regularly hold special intellectual property training for employees.
In January 2026, Betta Pharmaceuticals and Westlake University reached a cooperation. The two parties will provide special training on biological intellectual property rights.
Carry out school-enterprise collaborative innovation cooperation in the fields of life sciences and medical innovation to further improve
We are good at the full chain innovation of "basic research - technological research - achievement transformation - industrial application". During the reporting period, the company held special training on "Patent Protection and Breakthrough in New Drug Research and Development".
The new ecology effectively promotes the in-depth integration of technological innovation and industrial innovation, and provides regional development for key departments such as the Research Institute, Registration Department, Project Management Department, and Strategic Cooperation Department.
Inject new momentum into the high-quality development of the pharmaceutical and pharmaceutical industry. Door. The training focuses on the collaboration of patent layout and the entire process of drug research and development, with systematic explanations starting from
Patent strategy from target discovery to commercialization stage, focusing on analysis of each R&D stage
Betta Pharmaceuticals signed a contract with West Lake University
Intellectual property risks and opportunities, and clarify the compliance responsibilities and obligations of R&D personnel.
Special training on “Patent Protection and Breakthroughs in New Drug Research and Development”
Intellectual property protection
Indicators and Goals
Betta Pharmaceuticals is well aware of the industry characteristics of high investment, long cycle, and low success rate in innovative drug research and development. It attaches great importance to intellectual property and patent protection and builds a comprehensive knowledge base.
The property rights management system strengthens the prevention of intellectual property infringement risks and protects research and development innovation. The company sets internal management goals around R&D and innovation, and ensures that the management process is measurable and traceable by continuously monitoring the progress of goal achievement, conducting quantitative analysis and regular reviews. On this basis, the company further established systematic management indicators to dynamically monitor and evaluate the performance related to intellectual property management, provide scientific basis for setting goals in the next stage, and promote the continuous improvement of the company's innovative research and development.
Intellectual property protection management system
Management Indicators Unit 2025
The company abides by domestic and foreign laws and regulations such as the Patent Law of the People's Republic of China and the Trademark Law of the People's Republic of China, and formulates and implements internal systems and procedures such as the Intellectual Property Compliance Management Manual and the Intellectual Property Rights Compliance Management System Procedure Documents to provide adequate intellectual property work support for the company's technological innovation and patent applications. Proportion of operating income % 15.89 R&D personnel 298 The chairman of the company is the first person responsible for the company's intellectual property management, coordinating intellectual property strategy and decision-making on major matters. The company has established an intellectual property department to manage the company’s intellectual property rights.
Proportion of R&D personnel % 16.69 Carry out comprehensive coordination of work, track intellectual property risk monitoring, strategic planning, and technological innovation identification and evaluation throughout the entire life cycle of R&D projects.
Registered trademark items 376 registered patent items 238 work copyright items 9 patent risk management
Registered domain name Item 2 Software copyright Item 10 The company implements strict intellectual property risk management and control at all stages of R&D projects to ensure that product R&D and innovation are carried out without infringing the intellectual property rights of others, while effectively protecting R&D projects.
Several invention patent applications and 39 innovative achievements were made.
Several invention patents have been authorized 29. The company regularly conducts patent information retrieval and analysis, and continuously monitors competitors’ intellectual property trends. At key stages such as project establishment, key nodes of R&D, before project transactions, and before product launch, the company conducts infringement risk assessments, including free-to-implement investigations (FTO) and patent stability analysis, to prevent intellectual property risks in an all-round way. Invention patent items applied to main business 235
17 18
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Privacy protection and information security Product quality and security
Privacy protection and information security are key elements for corporate compliance operations. Betta Pharmaceuticals continues to improve the privacy protection and information security management system and improve the level of information security protection. Betta Pharmaceuticals deeply understands that product quality and safety are the core competitiveness of the company and the fundamental guarantee for fulfilling its mission. We strictly abide by international quality management standards and relevant standards, and effectively safeguard the information and privacy data security of the company and all stakeholders. During the reporting period, the company did not encounter any violations of laws, regulations and ethical standards due to privacy protection and information security. It always puts drug quality and patient safety first, and has established quality control covering the entire life cycle of R&D, clinical research, production and marketing, and was punished by relevant departments. management system to effectively ensure the safety of products and protect the health rights of patients. During the reporting period, the company had no major safety and quality liability accidents related to its products and services.
It has not received any administrative penalties from regulatory authorities.
Privacy Protection Governance 〇 Betta Pharmaceuticals Quality System
The company strictly abides by the "Consumer Rights and Interests Protection Law of the People's Republic of China", the "Personal Information Protection Law of the People's Republic of China" and other laws and regulations in the places where it operates to ensure that individuals and patients. The company strictly abides by the national drug regulatory laws and regulations system to ensure
The transmission and processing of bed data are legal and compliant. "Drug Administration Law of the People's Republic of China" and "General Principles of the People's Republic of China"
(GPD)
"Regulations on the Implementation of the Drug Administration Law of the People's Republic of China" and "Drug Production Quality Control"
In terms of data collection, the company strictly follows the principle of the minimum necessary, and based on the informed consent signed by the subjects, carries out individual standard operating procedures (SOP) within the scope permitted by laws and regulations and necessary for clinical trials.
"Current Good Manufacturing Practice for Pharmaceutical Products"
Collection, processing and retention of human and clinical data. At the same time, the company assigns subject identification codes to subjects to replace their real identity information to effectively protect the privacy of subjects.
Process Instruction (MPI)
(cGMP)", International Harmonization of Technical Requirements for Pharmaceuticals for Human Use
In external cooperation scenarios, the company adds data protection clauses to cooperation agreements with clinical trial partners to ensure that partners assume data protection responsibilities. For internal research personnel (ICH) "Q10: Drug Quality System" and other domestic master batch records (MBR)
The company requires employees participating in clinical trials to abide by confidentiality requirements. Each clinical study will provide researchers with instructions to protect the privacy of subjects before and during the conduct of each clinical study. External laws and regulations serve as the core framework to establish a pharmaceutical quality management system.
Quality Standard (SPC)
Special training. Tie. The company formulates and implements the "Quality Manual" and other
Standard Test Procedure (STP) Betta Pharmaceuticals Quality Management System Certification Department System. During the reporting period, the company’s ISO 9001 quality management system
System certification remains valid.
Data Security
The company has established a top-down, clear-level quality management structure. As the first person responsible for product quality and safety, the chairman of the board of directors coordinates and manages quality assurance by establishing a quality manager.
The Certification Department and Quality Control Department ensure clear quality management responsibilities, equal rights and responsibilities, and efficient operation. In addition, the company has established a responsibility assessment mechanism to incorporate quality and security responsibilities. Each company strictly abides by the "Data Security Law of the People's Republic of China" and other laws and regulations where it operates, and formulates and implements the "Information Security Management System" and "Data Backup and Recovery Management Level Position Performance Appraisal System."
System", "Computer System Emergency Response Procedures" and other internal systems, and continuously optimize the safety management process to ensure compliance operations.
strategy
At the technical level, the company continues to increase investment in the field of information security, deploying security situation awareness platforms, audit trails, strengthening data transmission encryption, proxy servers and defense
Multiple protection methods, including virus solutions, build a multi-level and three-dimensional protection network. At the same time, the company has established a complete data backup and recovery mechanism and regularly organizes
Backup and recovery drill verification ensures rapid business recovery under extreme circumstances and provides a solid guarantee for the company's business continuity. In order to accelerate the company's development into a leading innovative biopharmaceutical company, the company continues to strengthen its production quality system capabilities. This system covers the entire process from early R&D to commercial supply, with quality assurance as the core, and six major GMP-based management subsystems are built and implemented. In addition, the company's two major production bases in Hangzhou and Shengzhou are equipped with
Advanced API production lines, solid preparation production lines and fully automatic intelligent production lines have sufficient large-scale production capacity to produce high-quality drugs to meet the growing global market.
〇 Beida Pharmaceutical Information Security Control Measures
market demand.
Monitoring and Early Warning Access Control Through systematic risk identification and assessment procedures, the company conducts comprehensive research and judgment on potential impacts, risks and opportunities on product quality and safety, and formulates targeted policies based on this.
management strategies to ensure the compliance and sustainability of operational activities.
Deploy a security situation awareness platform to sense the security situation in real time. Configure a proxy server to strengthen network boundary protection.
Type Specific description Financial impact Countermeasures
Transmission Security Terminal Protection
Production compliance risks: Innovative drug production flow regulatory penalties and production suspension losses: if they occur 1. Strengthen GMP compliance management and optimize the strategic layout of production bases to pave the way for innovation
The process is complex, and clinical trial data authenticity and GMP compliance issues may face regulatory oversight. Establish a stable and controllable quality system for the commercial production of drugs; encrypt data transmission throughout the link to ensure the security of data flow. Deploy anti-virus solutions to build a strong terminal security defense line.
If there is a deviation in process stability, or the department imposes a fine or orders to stop production for rectification,
- Proactively identify management deficiencies through self-inspection and verification, and take timely measures to improve quality. Risk GMP compliance control is not in place, which may directly lead to production interruption, resulting in
measures;
Audit traceability and issuance of regulatory penalties will affect product launches, production capacity losses and revenue gaps.
- Optimize and improve the production and quality management system, and increase production through continuous learning.
Strengthen employees' understanding of laws and regulations, and strengthen employees' quality awareness. Establish a complete audit tracking mechanism to make behaviors auditable
Risks of adverse reaction monitoring: on innovative drugs Product recall and market withdrawal: if it occurs 1. A pharmacovigilance work organizational structure with clear rights and responsibilities has been established. After the company system is launched, if adverse reaction monitoring is not timely, serious adverse reactions are not handled properly, clinical trials and post-marketing safety data collection, analysis, identification and evaluation can be carried out.
Improper handling of risks may trigger safety warnings, trigger product recalls, or be regulated by regulators. Drug risk signals, write and submit safety reports; the company attaches great importance to the compliance of information security management, regularly organizes internal information security training, continuously reduces the legal compliance risks and reputational risks faced by the company, and promotes the company's credibility. Affect product market access and patient medication. 2. Through regular organization of business training involving all employees, and key department employees
Confidence and increased compliance costs. Resulting in a decline in sales revenue.
The level of information security continues to improve. Carry out special training to continuously improve employees’ awareness of pharmacovigilance.
19 20
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Impact, Risk and Opportunity Management Audit Institution Audit Scope Rectification Status
Hangzhou Municipal Food and Drug Administration on-site inspection of drug production license renewal No defective items
Hangzhou Municipal Food and Drug Administration's daily inspections (preparations, APIs, commissioned production and inspection, pharmacovigilance) are all general defects, and rectification has been completed. Quality risk management is an important part of the quality management system. The company formulates and implements the "Quality Risk Management System" to systematically evaluate, control and review product quality risks.
Based on scientific knowledge and process experience, we are committed to controlling risks within an acceptable range and reducing product quality risks. When conducting quality risk assessment, the company adopts the U.S. Food and Drug Administration (FDA) FDA official audit of ensartinib hydrochloride API. All are general defects, and has completed the rectification of professional risk rating tools such as FMEA (Failure Mode and Impact Analysis) to accurately quantify and grade management of quality risks, and formulate targeted response strategies to ensure that there is 1 major defect and 2 general defects.
Zhejiang Provincial Food and Drug Administration Biological Products for Therapeutic Use (Bevacizumab Injection)
The soundness and sustainability of the company’s operations. At the same time, the company has fully integrated product quality and safety into daily risk management, regularly conducted comprehensive risk assessments, and standardized and promoted risk rectification identification, assessment and response work (see the "Risk Compliance Management" chapter for details).
In order to ensure the quality and safety of products throughout the production cycle, the company adopts effective quality control activities in the stages of research and development, clinical research, technology transfer, commercial production, and product delisting.
Achieve full life cycle risk management and control to ensure product quality and safety.
〇 Betta Pharmaceuticals Quality Risk Management Flow Chart
〇 Quality control measures throughout the life cycle of Beida Pharmaceutical products
Risk Identification Gathering background information and data on potential sources of hazards, hazards, or effects on human health that are relevant to risk assessment.
In the research and development stage, pharmacology, toxicology and pharmacokinetic experiments are carried out to evaluate the safety and effectiveness of drug candidates to ensure compliance with scientific principles and ethical standards.
Analyze the identified hazard sources, evaluate the possibility and severity of exposure to the corresponding hazard sources, compare the analysis results with the risk standards, and determine
risk analysis assessment
Determine the risk level and whether it is acceptable.
Follow the "Good Clinical Practice Practice for Drugs" to ensure the protection of subjects' rights, data authenticity and trial compliance. Rigorously designed clinical trials, clinical research stages
Collect efficacy and safety data to provide a basis for registration.
Risk Control Reduce risk to an acceptable level and control measures are appropriate to the risk level.
Verify the transferability of the production process from R&D to production to ensure the stability and consistency of large-scale production. Establish a technology transfer management system and clarify the stages of quality technology transfer
Standards and handover processes.
Risk communication runs throughout the entire process to ensure that all relevant parties have a consistent understanding of risks and their management measures.
Comprehensively implement GMP management to ensure that raw material procurement, production process control, finished product inspection and other aspects comply with regulations. Establish a batch management and traceability system to strengthen the commercial production stage
Supplier evaluation and raw material quality control.
Risk review: Re-evaluate risk management control requirements based on risk management control effects or changes in trends.
Carry out post-marketing surveillance, collect adverse reaction data, evaluate efficacy and risks, and ensure that delisting decisions are based on scientific evidence. Implement the re-evaluation process and review the delisting phase of pharmaceutical products
product safety and quality stability.
Product quality system
Quality Training 〇 Beida Pharmaceutical GMP Training Classification
Pre-job training Annual training Other training
The company has formulated standardized and systematic quality assurance system documents to ensure that production activities are carried out in an orderly manner in strict accordance with established requirements and comply with specified uses and registration requirements. The company is committed to building a complete quality training system and attaches great importance to cultivating quality awareness among all employees.
Under the GMP system, for on-the-job employees, the company's product quality management system includes core components such as quality risk, quality control, quality inspection, and quality training based on business and compliance needs. Improvement of education and quality. We formulate and implement the "GMP Training Management System" to regulate
development, production, quality, etc., and always maintain the highest product quality. Flexible implementation, including standard GMP employee training procedures and requirements, mandatory requirements for new employees in drug production and quality-related departments, quality level, R&D, production, CAPA special training, verification after joining the company. After joining the company, you will participate in employee certification programs and verification deviation training of quality and other related departments.
All relevant employees participate in GMP training. All employees independently carry out any
Quality control covers GMP knowledge, production workers receive annual training and other training every year. Before working on GMP, everyone must have completed training and passed the relevant GMP assessment. company
production points, quality control methods and training, as well as those related to the position
The GMP training system is divided into pre-job training, annual training and other training. Legal theoretical training. Training related to skill improvement. The company has established and continuously improved the quality testing and monitoring system. Through laboratory testing and monitoring throughout the entire production process, it covers raw and auxiliary package testing, intermediate process monitoring, and process control.
manufacturing, product release testing and stability testing to ensure the excellence and stability of product quality. We regularly detect and eliminate possible quality issues in all products on the market in a timely manner
Pharmacovigilance
and safety issues.
In order to ensure the smooth development of pharmacovigilance work, the company has established the following departments from top to bottom:
The company always puts drug quality and safety first, and by building a complete drug
Internal self-inspection External audit Vigilance system to effectively participate in clinical trial subjects and receive treatment from marketed products Drug Safety Committee
patient rights and safety, and systematically and effectively manage the safety of drugs throughout their life cycle
The company has established a complete GMP self-inspection management system, established a self-inspection team, and quality assurance. The company accepts external audits from domestic and foreign regulatory agencies from time to time. During the reporting period, risks. The company formulates and implements the Pharmacovigilance Working Group including the "Spontaneous Reporting Procedure for Adverse Drug Reactions/Events"
The certification team formulates the "Annual Self-Inspection Plan" every year to ensure that GMP-related departments and district companies have received various domestic and foreign audits 4 times, and there are no serious deficiencies. for each
"Procedure", "Drug Safety Emergency Handling Procedures" and other regulatory and institutional documents. this
The domain shall conduct self-inspections and daily inspections at least once a year. The company has passed self-inspection verification and external audit. The company management has organized heads of various departments to conduct the entire inspection process.
In addition, the company has established a pharmacovigilance work organizational structure with clear rights and responsibilities, and appointed a pharmacovigilance team of the Ministry of Medicine.
Comply with laws and regulations and standards, proactively identify management deficiencies, take timely improvement measures, review and summarize, discuss the improvement suggestions put forward by the inspection team one by one and formulate improvement methods
The person in charge of pharmacovigilance and be equipped with full-time pharmacovigilance personnel.
Give. For problems discovered during self-inspection, the company strictly implements correction and prevention plans in accordance with requirements. At the same time, we conducted in-depth cause analysis of the defects discovered during the inspection and formulated special projects.
Measures (CAPA), in-depth analysis of the actual or potential causes of non-conformity, eliminate the CAPA rectification plan from the source, clarify the reasonable rectification time limit, and implement the rectification responsibilities to specific
In order to ensure the operational efficiency and work quality of the pharmacovigilance system, the company systematically carries out clinical trials and post-marketing safety data collection and analysis, promptly identifies and evaluates drug risks, eliminates hidden problems, and avoids the recurrence of similar problems. Organize responsible departments to ensure closed-loop management of issues and continuous improvement.
signal, write and submit periodic safety reports, and provide scientific support for product decisions.
21 22
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
〇 Betta Pharmaceuticals’ post-market drug pharmacovigilance measures 〇 Betta Pharmaceuticals simulated recall process
Adverse reaction information collection and adverse reaction report processing
Establish recall team, formulate recall plan, initiate recall, relevant parties respond to recall information, follow up on recall progress, prepare recall report
• Monitor the company's website and multimedia accounts to detect adverse reactions. • Use the pharmacovigilance database (eSafety) to enter safety data.
information. • Evaluate adverse reaction reports and submit them to regulatory agencies in a timely manner in accordance with regulatory requirements.
• Standardize employee reporting responsibilities to ensure timely notification of pharmacovigilance
department. Pharmacovigilance system and compliance complaint handling
• Promptly handle adverse reaction reports fed back by regulatory agencies. • Write and submit periodic product safety update reports to regulatory agencies. In order to ensure the safety of public medication, identify and control quality risks, and continuously improve the quality management system, the company has formulated a "User Complaint Handling Management System" to classify, investigate, feedback and record complaints to ensure that the handling process is standardized and traceable. The company has a full-time complaint handling specialist who will receive any written, electronic or oral communication (including emails, phone calls, or oral messages).
• Proactively conduct literature searches to identify safety issues reported in the literature. • Continue to improve the pharmacovigilance system in accordance with regulatory requirements.
etc.) and register customer complaint information, carry out comprehensive cause investigation and impact assessment, take appropriate corrective and preventive measures to achieve closed-loop management, and promptly respond to customers to follow up on product safety information.
product handling to ensure customer satisfaction and loyalty.
• Develop safety management plans for clinical trial projects to clarify adverse reaction reporting analysis and risk management
Process for collecting safety information in clinical trials. • Conduct case analysis and evaluation of adverse reaction reports received. 〇 Beida Pharmaceutical Complaint Handling Process
• Equipped with MedDRA and WHO-drug dictionaries for coding • Conduct regular analysis and evaluation to detect and identify new safety signals.
Adverse events and names of concomitant medications. Cause investigation and product disposal and
• Take appropriate risk management and control measures when necessary. Complaint information reception, CAPA activation and tracking, complaint closure
Impact Assessment Customer Response
Pharmacovigilance training for all employees in 2025 indicators and goals
In order to strengthen employees' understanding of pharmacovigilance and further ensure that the company sets internal management goals around product quality and safety, it develops a special CAPA rectification plan and clarifies the rectification time limit for the risk matters identified during the implementation of the goals. On the effectiveness of post-market drug safety information collection channels, the company further establishes systematic management indicators, conducts dynamic monitoring and evaluation of sustainable development-related performance, and provides scientific basis for the next stage of goal setting. During the period, the company carries out pharmacovigilance training for all employees, and the training content is based on the data to promote the continuous improvement of the company's innovative research and development.
Covers pharmacovigilance basics and regulations, learning about adverse events
In order to continuously optimize and improve the production quality management level of the company's marketed drugs, the company sets quality management goals and tracks their achievement. During the reporting period, the company's quality targets were all achieved. Reporting process and time limit requirements, etc.
Pharmacovigilance training for all employees in 2025
Management Target 2025
Safety risk management drug quality factory pass rate 100% achieved
In order to deeply explore the potential risks behind the safety information, the company's vigilance team regularly conducts systematic summary analysis of the collected safety information to identify safety signals, and based on this, write a summary analysis report and submit it to the regulatory authorities. Based on the accurately identified safety signals, the company carried out a comprehensive and in-depth assessment, focusing on the contents of the current product instructions.
The external quality audit pass rate is 100%, and the established risk control measures are judged to determine whether they are sufficiently effective to achieve reasonable risk control. Based on the evaluation results, the company promptly updated the product instructions
It is updated and improved to ensure that the information contained therein is accurate and comprehensive. At the same time, the company clearly communicates drug risks and response suggestions to doctors and/and patients in a timely manner to ensure that risk information can be
It must not lead to a shortage of medicines in the market or discontinuation of medicines by patients. This link can be quickly and accurately transmitted, thereby achieving effective control of risks, effectively ensuring the safety of patients' medication, and safeguarding the health rights of patients.
There were no major quality incidents throughout the year and no more than 2 general quality incidents were achieved.
product recall
Management Indicators Unit 2025
In order to effectively protect the rights and interests of patients and ensure product safety, the company implements strict monitoring of products on the market and has established a complete product recall process. The company formulates and implements "Product
Internal system documents such as "Recall Management System" and "Simulated Recall Plan" strengthen the company's emergency management of emergencies on marketed products, improve the ability to respond and the execution of voluntary recalls when products appear hazardous or potentially hazardous, eliminate or reduce the extent and scope of hazards to a minimum, and ensure the safety of public medication.
Number of product and service complaints 7 In order to verify the effectiveness of the drug recall system, during the reporting period, the company carried out a simulation exercise for the active recall of bevacizumab injection products. The results of the exercise showed that all processes were
The complaint handling rate is 100% in line with the system requirements, and the company's drug recall procedures are operating effectively.
23 24
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Clinical trials and subject safety When selecting CROs, the company strictly selects CROs with laboratory animal use licenses, International Association for Assessment and Certification of Laboratory Animals (AAALAC) and other qualifications, and requires CROs to strictly follow ethical standards for animal welfare protection through agreements. At the same time, the company requires them to comply with the relevant regulations of the Laboratory Animal Use and Care Committee (IACUC) and manage and use experimental animals in a humane and scientific manner.
The rights and safety of subjects are the company's primary consideration, taking precedence over the benefits of experimental drugs to science and society. During the clinical trial process, the company abides by the "Drug Clinical Trials". For cooperative CROs, the company's relevant researchers regularly review the CROs to ensure compliance with animal welfare ethics regulations. In addition, the company has complied with the laws and regulations of the place where it operates, such as the Quality Management Standards for Bed Testing of Personnel Related to Animal Experiments in Research Institutes, the Regulations on the Administration of Drug Clinical Trial Institutions, and other laws and regulations of the place where it operates, and ensures compliance with the Declaration of Helsinki of the World Medical Assembly. All of them have obtained the "Laboratory Animal Practitioner License" issued by the competent authority of the place of operation to ensure that they understand the relevant contents of experimental animal ethics. The company's research institute also stipulates principles and related ethical requirements from time to time. During the reporting period, the company did not violate clinical trial ethics and was not punished by relevant departments. Conduct training on experimental animals, covering animal welfare, animal ethics, 3R2 principles, etc.
sustainable supply chain
Clinical Research Risk and Safety Management
Betta Pharmaceuticals firmly believes in the importance of good supply chain management in promoting the company's sustainable development. The company is committed to integrating the concept of sustainable development into the supply chain management system. The company always puts the protection of the rights and interests of subjects and the compliance of clinical trials first. It continues the rigorous standards of the clinical research center that has passed the US FDA GCP on-site inspection and established a complete
We will implement responsible business practices and work with partners to build a resilient and sustainable supply chain.
Improve clinical trial quality management system, subject protection mechanism and adverse event collection mechanism.
Subject protection mechanism
supply chain management
The company believes that throughout the entire process of clinical trials, ensuring the safety of subjects and promptly identifying and controlling risks are top priorities. The company obtains regulatory and ethical approvals before conducting clinical studies.
Approved by the committee, which is composed of people from various fields such as medicine, pharmacy, law, and community representatives, ensuring the independence and impartiality of the review work.
The company has built a systematic supplier management system, formulated and implemented internal systems such as the "Supplier Management System" and "GMP Material Management System", and established that the process of supplier selection and informed consent is the core link to protect the rights and interests of subjects. The company implements full life cycle standardized management for this. We conduct full and objective communication with subjects, confirm the standardized process for entry and exit, and use risk management and quality audit as dual guarantees to ensure that procurement activities are compliant and orderly, and promote the healthy and stable development of the supply chain.
Make sure they clearly understand the possible risks and potential benefits of the trial. Subjects have sufficient time to weigh and decide independently whether to participate in or withdraw from the trial. For vulnerable subjects, the public
When cooperating with small and medium-sized enterprises, we always follow the principles of fairness, impartiality and transparency, and give equal business opportunities and respect to small and medium-sized enterprises as well as large enterprises. To create fair competition, we need to obtain the legal written informed consent of the guardian, and at the same time, consult the subject's wishes when he or she has the ability to understand.
competition, mutual benefit and win-win market ecology. During the reporting period, the company had no overdue payments to small and medium-sized enterprises.
The company strictly regulates the management of informed consent for clinical trials, and relevant informed consent forms must be strictly reviewed and approved by the ethics committee before they can be used. If the clinical research plan changes
Furthermore, the company will submit the revised plan to the ethics committee for approval in a timely manner, and simultaneously inform the subjects of the relevant content to effectively protect the safety and legitimate rights and interests of the subjects. 〇 Beida Pharmaceutical Supplier Management System
〇 Clinical trial ethics review and subject rights protection mechanism Supplier screening Supplier admission Supplier withdrawal
When the company is looking for suppliers, it will conduct on-site inspections of potential suppliers and conduct annual review analysis and comprehensive assessment of potential suppliers when introducing new suppliers. The company conducts supplier quality assessments every year and conducts before the start of clinical trials. During the execution of clinical trials, ethical review mechanisms are in place. Review the results and eliminate unqualified suppliers in a timely manner; conduct annual routine reviews of the company's test plans, informed consent forms, plan revisions during research execution, and important safety issues for all ongoing research projects
A quality management system that implements laws and regulations and complies with company quality standards. In the event of serious quality problems or those who do not cooperate with the company, the qualifications and risk management plans must pass changes such as unique risks, and special review of ethics and key projects must be submitted in a timely manner to achieve clinical control.
Appropriate administrative licensing information. For suppliers under investigation, the company promptly initiates a comprehensive review by the Ethics Committee (IRB/IEC). Trial compliance and implementation of subjects’ rights
Cancel the change of supplier, check from qualified suppliers, and start only after passing the review. full supervision.
Clear the directory.
Adverse event collection and risk management are important components of the company's pharmacovigilance system during the clinical trial phase. In accordance with relevant regulatory requirements, the company conducts clinical trials
The company attaches great importance to the sustainable development of the supply chain and insists on building an honest, compliant, transparent and standardized
During the reporting period
Continuously collect adverse events, monitor risks and take effective risk control measures in a timely manner. All clinical projects under development of the company conduct standardized follow-up of subjects and closely monitor subjects.
Supply chain system. In the supplier access process, the company clearly embeds it in the cooperation agreement
security to ensure the authenticity, integrity and scientificity of clinical trial data. (For details, please refer to the "Product Quality and Safety - Pharmacovigilance" chapter in the report) Material suppliers have signed the prohibition of commercial bribery clause at a high rate, requiring suppliers to promise not to
Providing improper benefits to our employees in the form of cash, gifts or any other form. 100%
If a supplier violates relevant agreements, the company will suspend or permanently cancel its cooperation qualifications.
nonclinical animal research
Supplier business ethics reporting email: [email protected]
The company abides by the "Good Quality Management Practices for Non-Clinical Drug Research" and other laws and regulations in the places where it operates. In the early stages of drug development, because the company did not have its own animal laboratory, the company commissioned contract research
Research Organization (CRO) to conduct non-clinical safety evaluation research. 2.3R principle refers to: substitution, reduction, optimization.
25 26
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Supplier quality management Supply chain stability
In order to improve the quality management level of the supply chain and ensure the safety of products from the source, the company clarifies material suppliers, service suppliers and entrusted production suppliers based on internal systems. The company constantly explores the stability of material supply, controls possible risks in each supply chain link involved, ensures business continuity, reduces possible non-quality management regulations for the company's production, and covers the full life cycle management of supplier screening, changes, audits, maintenance and review. Good influence. The company formulates and implements the "Supply Chain Safety Management System", regularly conducts risk analysis on different material suppliers in terms of risk identification, possible losses and avoidance measures, and formulates corresponding guarantee plans to ensure the on-time supply of production materials.
〇 Supplier quality control process
〇 Supply Chain Security and Stability Initiatives
Supplier survey
Dual source supply, advance purchase, localized core materials
Distribute basic supplier information questionnaires and supplier quality system self-assessment questionnaires to potential suppliers, and request relevant quality qualification documents.
For the supply of key raw materials and high-risk materials with special requirements, the company has formulated multiple. For imported key materials, the company selects suitable materials. The company implements a dual-source supply strategy, channel procurement, appropriate stocking and other preventive measures to domestically produce supplier products that meet production needs.
Supplier change
Reserve 2 or more fixed suppliers and require implementation to avoid the risk of untimely supply; for customization and substitution, prevent key materials from being notified and provided in advance when materials are in short supply due to climate, distance, policies, negotiation with suppliers, advance arrangements and other factors that may lead to inability to deliver materials in time or failing to meet survey requirements. The company grades the materials supplied by suppliers and carries out qualification review, quality system confirmation, process confirmation, stability testing and other requirements.
solutions to ensure supply stability. Annual production and purchasing plan. the problem of sufficient supply, and at the same time in emergencies
Consider using alternative suppliers.
Supplier quality audit
Conduct quality audits on suppliers classified by level to ensure that the products provided by suppliers comply with relevant regulatory requirements and the requirements of Betta Pharmaceuticals.
〇 Quantitative indicators
Supplier Quality Agreement
Number of suppliers Unit 2025
The company signs a quality agreement with its material supplier, in which the quality responsibilities of both parties should be clearly stated.
Total number of suppliers 1,695
Supplier Quality Review
1,528 companies in mainland China conduct annual supplier quality assessments, on-site quality audits, quality inspection results of supplied materials, quality complaints, defects or abnormality handling and services in the previous year
Quality, etc. are reviewed.
Hong Kong, Macao and Taiwan Region Home 3
Overseas Regions Home 164
Based on the criticality of supply, the company implements four-level classification management of suppliers A, B, C, and D, and conducts periodic quality management audits. We proceed according to different categories of suppliers
Conduct paper audits, on-site audits, video audits and entrusted third-party audits, issue audit reports, put forward requirements for improving quality management, and strictly implement corresponding management
standard.
responsible marketing
〇 Betta drug material supplier audit cycle
Material level Quality audit cycle The company strictly follows laws, regulations and management measures such as the Advertising Law of the People's Republic of China and the Interim Measures for the Review and Management of Advertisements for Drugs, Medical Devices, Health Foods and Formula Foods for Special Medical Purposes, and formulates and implements the Commercial Sales Management System. The company strictly implements the marketing content control mechanism and standardizes the review of external promotional materials and marketing of A-level suppliers. The company conducts dynamic on-site audits according to different categories.
Full-process management of activities to ensure that all marketing activities are authentic and legal, and to eliminate false and misleading content.
For B-level suppliers, the company conducts on-site audits every three years, and imported excipients conduct paper audits every two years.
The company regards responsible marketing auditing as an important part of compliance management. The Internal Control Affairs Department conducts independent inspections on the promotion activities of marketing and other relevant departments, focusing on promoting C-level suppliers. The company conducts on-site audits every five years, and conducts paper audits of imported excipients every two years on compliance in the form of compliance and the implementation of internal processes. The company signed a "Compliance Sales Commitment" with designated cooperative pharmacies, requiring them to provide accurate and comprehensive drug information, not to exaggerate the efficacy of drugs, and not to mislead consumers. Respect patients' right to know, clearly inform drug prices, usage, dosage, possible side effects and other information, and do not engage in unfair D-level suppliers. The company conducts paper audits every three years
Competitive or illegal advertising.
The company has formulated the "Management Rules for Publishing Process" to ensure the compliance, accuracy and professionalism of the company's public marketing materials and prevent brand and compliance risks. The company establishes and implements continuous communication activities with the supplier's technical personnel. For key material suppliers, the company regularly provides guidance and training to improve their technical capabilities and quality system construction capabilities.
A three-level review mechanism is implemented, covering the entire process from manuscript submission to final confirmation, to ensure that all externally released marketing content meets regulatory requirements and the company's brand image. capabilities and GMP compliance. During the reporting period, the company carried out regular technical exchanges and consultations with suppliers for customized materials such as BPI-2009-04, ENA, ENB, D-0316, etc.
Capacity building.
27 28 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolence and mutual support
Bebe Dada Pharmaceutical Co., Ltd. || 22002255 Annual Cocoa Sustainable Development Development Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
environmental management
Betta Pharmaceuticals strictly abides by the "Environmental Protection Law of the People's Republic of China" and other relevant environmental laws and regulations, industry standards and norms, improves the environmental management system, implements environmental protection responsibilities, and continues to improve environmental management levels.
environmental management system
The company has formulated and implemented 19 environmental management systems including the "Environmental Protection Target Responsibility System", "Environmental Governance Management System" and "Environmental Target Management System", covering the entire process of source control, process supervision and end-of-line governance.
The company has clarified that the person in charge of the production center is the main person in charge of environmental protection, the EHS department is the specific management organization, and the R&D center, production workshop, quality control department and other departments perform their respective duties, building a four-level environmental governance structure of "decision-making leadership - supervision and management - execution cooperation - full participation".
Responsibility level Responsible subjects Core roles Overview of main responsibilities
• Enforce regulations;
• Lead the establishment of management systems;
• Approval policies and objectives;
Decision-making leadership Head of production center Main person in charge of environmental protection
• Serve as emergency commander;
• Make major environmental decisions;
• Securing resources.
Low Carbon Operation 03 • Prepare and revise rules and regulations;
• Manage pollution prevention facilities;
• Organize emergency training drills;
Supervisory Management EHS Department Specific Environmental Protection Management Organization
• Carry out environmental education;
green escort
• Dealing with pollution incidents;
• Responsible for environmental assessment, monitoring and system certification.
• Improve processes to avoid high risks;
• Develop cleaner production measures;
R&D Center Source Control and Process Improvement
• Manage laboratory waste classification; contribute to SDGs. Betta Pharmaceuticals follows the green development guidelines of “lucid waters and lush mountains are valuable assets”, • organizes rescue operations and reports when accidents occur. Pay attention to ecological and environmental protection as an important support for the sustainable development of enterprises • Transform equipment to improve airtightness; implement coordination layers
Support. Betta Pharmaceuticals integrates green and low-carbon concepts into the entire business process and strictly organizes employee operation training;
Production workshop process control and standardized operations
On the basis of adhering to the bottom line of environmental protection compliance, transform ecological advantages into sustainable enterprises • Reduce waste of raw materials and auxiliary materials;
industry competitiveness. • Organize rescue operations and report incidents when accidents occur.
• Manage laboratory waste classification; Quality Control Department Laboratory Waste Management
• Organize rescue operations and report incidents when accidents occur.
• Participate in environmental protection training;
• Comply with rules and regulations;
Basic participation level All company personnel System compliance and basic supervision
• Report hidden dangers promptly;
• Stop work and report hazards.
29 30 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolence and mutual support
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
〇 Emergency response procedures for sudden environmental pollution accidents
During the reporting period, the company’s icotinib hydrochloride tablets and ensartinib hydrochloride capsules production base
environmental pollution incident
The relevant environmental management activities involved have passed the ISO 14001:2015 environmental management system
Certification 3.
emergency leadership group
Emergency Command
Company Commander-in-Chief: Head of Production Center
Park Management Committee Tel: 89266096
did not happen
Environmentally friendly
Firefighting
Situations in which major administrative penalties are imposed due to environmental violations. emergency start
Public Security Comprehensive Coordination Group
external force
Medical On-site Rescue Team Company ISO 14001:2015 Environmental Management System Certification Certificate
Emergency firefighting team on-site cleanup and rescue operations Material dispatching team compliance risk management and control Lifting the alert Environmental protection team handling the aftermath Logistics support team
emergency recovery
Accident Investigation Information Release Group Company formulated and implemented the "Environmental Risk Management System", improved the environmental risk management and control mechanism, and carried out systematic inspections of key places such as production workshops, hazardous chemical warehouses, and environmental protection facilities.
Identification of sexual environmental risks, focusing on secondary environmental accidents caused by leaks and explosions in production processes, leaks and fires in storage areas, abnormal operation of environmental protection facilities and harsh natural conditions
Risk scenarios must be identified and environmental risk identification and assessment must be carried out regularly. Site cleanup
emergency end
Disarm
〇 Environmental risk dynamic management and control process
Normalized development
environmental management objectives
The company continuously organizes or entrusts professional institutions to identify and evaluate environmental risks in the factory area, identify hazard sources and risk factors, and regularly review control results.
In accordance with the laws, regulations and standards related to environmental protection of the People's Republic of China and the places where it operates, the company formulates and implements the "Environmental Target Management System" to clarify the emission control requirements for wastewater, waste gas, noise, solid waste and other pollutants. It ensures the effective implementation of various indicators by formulating annual environmental targets every year and carrying out regular monitoring and tracking.
Dynamic trigger start
Goal Goal content Goal value
When laws and regulations change, new construction projects are implemented, operating procedures are adjusted, etc., risk identification and evaluation are re-carried out in a timely manner.
Waste water discharge meets the standard 100%. "Three wastes" meet the standard discharge 100%. Waste gas discharge meets the standard and VOCs emission reduction meets the requirements. 100% solid waste disposal meets the requirements. 100%
Results transformation application
Third-party EHS audit pass rate 100% External audit pass rate 100%
The timely response rate of external audit CAPA is 100%. Based on the identification and evaluation results, the emergency plan for environmental emergencies is revised and filed in a timely manner, emergency facilities and materials are equipped, and daily supervision and inspection are implemented.
During the reporting period, the company fully completed various environmental management goals.
Environmental emergency management
Environmental awareness training
The company formulates and implements the "Environmental Emergency Management System" and establishes an emergency response flow of "discovery alarm-emergency activation-on-site disposal-external linkage-emergency recovery-emergency termination"
process, regularly carry out emergency plan preparation and emergency drills, and continuously improve emergency response capabilities.
The company formulates and implements the "Environmental Protection Training and Education System". The EHS department uniformly organizes and implements environmental protection training, and conducts guidance, inspection and supervision of various departments. The training covers all departments. The company has established an emergency leadership group headed by the person in charge of the production center, which is fully responsible for the organization and implementation of the process, including the formulation of pre-plans and material reserves, and the command and rescue of employees, external contractors and visiting interns during the incident.
Coordination with external parties, post-incident investigation and plan revision.
The company has established a hierarchical and classified training system, formulates annual training plans every year, uses a combination of centralized teaching and independent learning to conduct training, establishes environmental education management files, and implements full-process management of training, assessment, and archiving.
- The production addresses involved include: No. 355 Xingzhong Road and No. 24 Wuzhou Road, Economic and Technological Development Zone, Linping District, Hangzhou City, Zhejiang Province
31 32 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Training objects Training content Coping with climate change
New employees focus on basic training on environmental protection regulations, management systems, pollution prevention and control, etc.
Production center employees strengthen practical training on hazardous waste management, environmental risk identification, emergency response, etc. Betta Pharmaceuticals follows the relevant national policies on climate change, integrates climate change response into corporate strategy and daily operations, systematically carries out the identification and analysis of climate-related risks and opportunities, improves response mechanisms, and promotes the company's low-carbon development.
Personnel in environmental protection positions are provided with special skills training on wastewater and gas treatment, environmental monitoring, emergency response to environmental emergencies, etc., and must pass the assessment before taking up their posts.
governance
The company incorporates climate change response into the scope of environmental management and sustainable development, and coordinates and promotes climate-related management work in conjunction with the corporate governance structure. The company combines industry characteristics and operational realities to clarify the management responsibilities of each level in environmental and climate-related matters, and steadily promotes the implementation of low-carbon operations and energy conservation and carbon reduction measures. The company's Board of Directors and Sustainability Committee, as the highest decision-making bodies, are responsible for overseeing climate-related risks and opportunities. The management coordinates goal setting and cross-departmental coordination, and each business unit implements specific measures such as energy efficiency improvement and carbon emission control. The company continues to pay attention to climate-related risks and opportunities, continuously improves internal management requirements, and improves management levels in response to climate change.
strategy
Environmental protection training site
In line with the national "double carbon" policy and the green development requirements of the pharmaceutical industry, the company has incorporated climate change response into its corporate development strategy, and promoted it in a coordinated manner with environmental management, energy conservation and emission reduction. Relying on the existing environmental management system, the company carries out energy conservation, emission reduction and carbon reduction work in the production process. Through continuous optimization of production processes, it improves energy utilization efficiency, accelerates green process research and development, improves the operating efficiency of polluting facilities, etc., promotes the low-carbon development of the company's production operations, and achieves green development and clean production of the company.
Practice green office
During the reporting period, the company carried out a systematic assessment of climate-related risks and opportunities based on the characteristics of the biopharmaceutical industry, its own R&D, production, and sales chain business layout and multi-regional operations, formed a list of climate risks and opportunities, and formulated targeted response measures to promote the deep integration of climate risk management and corporate operations.
The company integrates the concept of green development into the entire process of office operations, and carries out green office practices focusing on cost reduction, efficiency improvement, low-carbon emission reduction, and resource recycling. During the reporting period, the company’s business-related departments
We have established cost reduction and efficiency improvement working groups in multiple campuses of the United Door, regularly carry out publicity activities such as energy saving and low-carbon travel to enhance employee awareness, and established a grid part-time group to carry out energy saving and efficiency reduction work in office areas.
〇 Risks from climate change
Carry out daily supervision and rectification on consumption, resource recycling and other situations.
Types of climate-related risks Risk description Financial impact Countermeasures Time horizon 4
• Energy saving and consumption reduction: Promote energy-saving transformation of electricity consumption and install intelligent power-off switches and induction lighting devices;
• Extreme weather can easily cause production and material • May increase facility maintenance, • Strengthen facility disaster prevention and insurance protection, stabilize supply and implement energy-saving renovation of air conditioning systems and underground garage lighting;
Acute physical risks Flow and supply chain interruption, affecting research and development business interruption, drug damage Supply chain and drug quality, improve emergency response S
• Resource circulation: Promote office supplies sharing and digital office, through online approval, document transmission and operational continuity. consumption and emergency management costs. ability.
physical risk
Reduce paper consumption through delivery and other methods; standardize the classification and collection of domestic waste, and set up classification and recycling facilities. • Promote energy-saving and water-saving transformation, optimize equipment operation and maintenance. and raw material supply system.
should be stable. cost.
• Low-carbon travel: Promote online meetings to reduce the frequency of people traveling; build shared charging piles and other facilities • Compliance renovation costs are rising,
• Dual-carbon and environmental protection policies are becoming stricter, and more • Track policy trends, promote low-carbon transformation, and strengthen policies and laws. There are M and L measures such as production restrictions and penalties to guide employees to travel green. Regional operations face compliance pressures. chemical compliance management
risk.
• Market requirements for low carbon levels are gradually increasing • Market expansion and financing costs
• Improve the level of green operations, strengthen green R&D market improvement, affect corporate competitiveness and cost pressure, transformation investment and information disclosure.
investment and financing environment. Increase.
• Track low-carbon technologies in the industry and pay attention to the transformation risks of the pharmaceutical industry • The cost of transformation is high, and there are mature energy-saving, consumption-reducing and emission-reducing technologies.
• Low-carbon technology iterations are accelerating, and existing
Technology In Investment and Operational Efficiency • Strengthen technology verification and evaluation, adopt pilot projects first and then L process equipment has the risk of falling behind.
Uncertainty. Promote the model to improve technical applicability and investment efficiency.
• Strengthen low-carbon environmental management: continue to improve the environment
• Not conducive to business cooperation and
• Insufficient low-carbon and environmental protection performance may affect management level and establish a responsible corporate image. Reputation financing increases brand repair and affects brand reputation and market trust. • Standardize climate disclosure: Proactively and transparently cover costs.
Disclosure of environmental protection and low-carbon work results
Betta Pharmaceuticals energy-saving publicity activities Betta Pharmaceuticals energy-saving office posters 4. Short-term (S): within 1 year (including 1 year); medium-term (M): 1 to 5 years (including 5 years); long-term (L): more than 5 years
33 34
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
〇 Opportunities brought by climate change
energy use
Climate opportunity classification Opportunity description Financial impact Time horizon
• Optimize resource management, promote resource recycling in R&D and production links • Reduce resource consumption and procurement costs, and optimize operating cost results. Betta Pharmaceuticals strengthens refined energy management, promotes energy-saving technological transformation, continues to optimize the energy use structure, and continuously improves energy utilization efficiency.
Resource efficiency M
Environmentally friendly utilization improves resource utilization efficiency throughout the entire process. structure to increase profit margins.
• Promote energy-saving transformation, promote the application of renewable energy, optimize • Reduce traditional energy expenditures, enjoy policy subsidies, and avoid
Energy Utilization M
The energy consumption structure is in line with the trend of upgrading energy efficiency standards. High energy consumption penalties are imposed to control costs and increase profits. energy management
• Relying on low-carbon operations and good ESG performance to expand cooperation space • Reduce financing costs, drive revenue growth, and enhance brand profit
Market M
time, attract green investment, and enhance market competitiveness. price and optimize profitability. The company formulates and implements the "Energy Management and Assessment System" to implement full-process management of major energy sources such as electricity and natural gas. Through energy consumption statistics, monitoring and analysis, it regulates production and non-production energy use behaviors, and implements an assessment mechanism that combines rewards and punishments to restrict illegal energy use behavior and provide incentives to departments or individuals with outstanding energy-saving results.
• Green innovative products can open up new market demands and drive research and development
• Use degradable/recyclable packaging materials (reduce packaging waste
Product and service development translates into revenue growth; green production services can improve customers. Companies M and L have established a three-level energy management structure of company, department, and team, clarifying the energy management responsibilities of each relevant department and position, and forming an energy management network covering all employees. The carbon footprint of materials and transportation meets the industry’s low-carbon development needs.
Stickiness, increase service revenue
• Improve infrastructure protection, supply chain buffering and emergency response systems, • Reduce business interruption and maintenance costs, and ensure stable revenue. Responsible entities Core responsibilities
Toughness L
Improve operational resilience and resist climate-related risks. Improve financial stability and risk resistance.
Energy Management Leading Group (Team Leader: Vice President in Charge of Production) Responsible for energy decision-making, system review and implementation plan approval
The Equipment Department is responsible for daily coordination, energy consumption statistics, metering management and energy facilities renovation; the Finance Department is responsible for the Energy Statistics Equipment Department (functional department) and the Finance Department (collaborative department)
Accounting summary, analysis and utilization report
Impact, risk and opportunity management
Each team is responsible for the rational use of energy and completing energy-saving targets; the part-time energy manager assists each team and part-time energy manager responsible for the unit's energy
People carry out daily supervision and inspection
The company integrates climate-related management requirements into the existing risk management system and conducts evaluation and improvement on a regular basis. The company combines business layout, operating area characteristics, external policies and industries
Dynamically, prioritize the importance of identified climate-related risks and opportunities, track the implementation of response measures, and continue to improve climate resilience.
Energy saving renovation
Metrics and Goals
The company has implemented a number of energy-saving transformations around the two major energy categories of electricity and steam, and continues to reduce energy consumption through equipment upgrades and process optimization.
The company continues to strengthen greenhouse gas emission control and promote green and low-carbon development throughout the entire operation process. The company implements emission reduction measures by improving energy utilization efficiency and optimizing energy structure. • Equipment upgrade: The company will change the production water supply from constant pressure unit pressurization to municipal direct supply to reduce the power consumption of the pump unit, and reduce steam leakage losses by replacing high-efficiency energy-saving traps. measures to continuously improve the level of climate governance.
• Process optimization: The company adjusted the cleaning frequency of intermediate production from cleaning every batch to cleaning once every four batches to simultaneously reduce electricity and steam consumption.
〇 Quantitative indicators
〇 Quantitative indicators
Energy Unit 2025 Key Indicators Unit 2023 2024 2025
Comprehensive energy consumption tons of standard coal 2,946.88 Scope 1 greenhouse gas emissions tons of carbon dioxide equivalent 2,282.73 2,023.91 1,267.74
Scope 1 greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 0.93 0.70 0.35
Comprehensive energy consumption intensity tons of standard coal/million revenue 0.82 Scope 2 greenhouse gas emissions tons of carbon dioxide equivalent 10,876.99 8,459.80 11,171.77
Scope 2 greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 4.43 2.93 3.10 Diesel consumption liters 1,332.67Scope 3 greenhouse gas emissions tons of carbon dioxide equivalent 121,112.90 114,778.61 151,301.66
Gasoline consumption (for business travel) Liter 6,227.56 Scope 3 Category 1 - Outsourced goods and services Ton carbon dioxide equivalent 118,103.64 110,744.50 147,467.04
Scope 3 Category 5 - Waste generated in operations tons of carbon dioxide equivalent 1,520.40 2,674.74 2,524.16
Natural gas consumption cubic meters 571,887.00 Scope 3 Category 7 - Employee Commuting Ton CO2 equivalent 1,488.86 1,359.37 1,310.46
Scope 3 greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 49.31 39.69 41.92 Purchased electricity kWh 17,716,810.00Total greenhouse gas emissions tons of carbon dioxide equivalent 134,272.62 125,262.32 163,741.17
Purchased steam tons 5,978.65Greenhouse gas emission density tons carbon dioxide equivalent/million revenue 54.67 43.31 45.37
35 36
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Resource Management Emissions Management
Betta Pharmaceuticals attaches great importance to resource conservation and recycling, and continues to promote the recycling of water resources and the reuse of packaging materials. Betta Pharmaceuticals has established an emissions management system covering waste gas, waste water, noise and solid waste, strictly implements various management systems, and improves the management and control processes of each link.
water resources management
The company strictly abides by laws and regulations such as the Environmental Protection Law of the People's Republic of China, the Air Pollution Prevention and Control Law of the People's Republic of China, the Water Pollution Prevention and Control Law of the People's Republic of China, the Noise Pollution Prevention and Control Law of the People's Republic of China, the Law of the People's Republic of China on the Prevention and Control of Environmental Pollution by Solid Waste, and formulates and implements the Waste Gas Management System and Wastewater Management System. "Solid Waste Management System", "Hazardous Waste Management System" and "Noise Management System", establish a full-element emissions management system covering waste gas, waste water, noise, solid waste and hazardous waste. The company has established a water resources management system covering the entire process of water intake, water use and recycling, with tap water and steam as the main water sources to ensure production and domestic water needs. The company opens
system.
Conduct water balance tests to systematically understand the status of water use in each link, formulate water-saving improvement measures, and continuously improve water resource utilization efficiency.
• Daily office water management: Domestic water in the company's office areas is uniformly supplied by tap water, and office spaces such as complex buildings are equipped with independent water meters. Through water-saving publicity and communication, the company has made it clear that the person in charge of the production center has the overall responsibility for emissions management, and has established a three-tier governance structure of "decision-making-supervision-execution". The EHS department coordinates system formulation, facility operation, and regular inspections of emissions to continuously standardize water use behavior and eliminate leaks and leaks. In terms of monitoring and information reporting, the R&D center and production workshop implement emission reduction measures from the aspects of process optimization and production control respectively to ensure that all types of pollutants are discharged stably and up to standards.
• Factory production water management: The company's production water covers the main production system, auxiliary production system and recycling link. Each water unit is equipped with secondary or tertiary water metering as required.
measuring instruments. The company has established a multi-department linkage management mechanism. The production center collects water use data on a monthly basis. The equipment department is responsible for the ledger management of water use and major energy-consuming equipment. The finance department has established
Management level Responsible entities Core responsibilities
Water resource consumption statistical ledger, timely analysis, reporting and disposal of abnormal water use situations. The company through cooling water recycling, steam condensate reuse, pure water preparation and utilization
use to continuously improve water resource utilization efficiency.
Decision-making level Head of Production Center As the main person in charge of EHS work, he is responsible for the management of noise, exhaust gas, waste water and solid waste
Category of water resource recycling. Description of results. Formulate various management systems, operate and maintain prevention and control facilities, carry out emission monitoring, and regularly report emission information; equip protective equipment; monitor EHS departments at the supervisory level.
Implement classified collection, temporary storage and entrusted disposal of hazardous wastes
Cooling water recycling The indirect cooling water circulation rate of the cooling system reaches 99%
Steam condensate water reuse The steam condensate water reuse rate is 64.4%, which is collected and used to replenish water in the cooling system.
R&D center optimizes the production process and equipment selection, giving priority to low-noise equipment; reduces the use of toxic and harmful raw materials, and reduces the generation of pollutants from the source. The preparation of pure water adopts multi-stage media filtration + two-stage RO + EDI process, with a pure water yield of 75.2%. The prepared pure water is used for process production, quality inspection and
Pure water preparation and utilization execution layer
Cleaning and disinfection
Production workshop: Finely control the production process to ensure the normal operation of equipment and reduce the generation of various pollutants; effectively distinguish between thick and thin wastewater, and mixed discharge is strictly prohibited
〇 Quantitative indicators
Key Indicators Unit 2025
Waste gas emission management
Water consumption cubic meters 231,406.00
Water consumption density cubic meters/million revenue 64.11
The company's waste gas is mainly divided into process waste gas, dust waste gas and sewage station waste gas, which mainly comes from production workshops, R&D laboratories and sewage treatment stations. The company adopts classified management and establishes management mechanisms such as facility inspections and regular monitoring to ensure that waste gas emissions meet standards.
Packaging material management
• Process waste gas: contains organic and inorganic pollutants. After multi-stage pretreatment such as condensation, spraying, and adsorption, it is uniformly connected to ENN Energy for incineration disposal.
• Dust exhaust gas: comes from the production process of the preparation workshop, and is discharged at high altitude after high-efficiency filtration, bag dust removal and water spray purification.
The company formulates and implements the "Reusable Packaging Container Management System" and implements closed-loop management of turnover barrels, pallets, special transfer containers, etc. used in the factory to minimize the need for reusable packaging containers.
Sexual packaging waste is generated. The company has established a cross-departmental collaborative management structure to clarify the full-process supervision of packaging materials from procurement and evaluation, receipt and use, cleaning and maintenance to decommissioning and disposal, ensuring that packaging materials • Sewage station waste gas: mainly contains odorous gases. After collection, it is connected to ENN Energy together with pre-treated process waste gas for incineration and disposal. Standardize recycling, safe use and compliant disposal.
The company promotes the reuse of packaging materials and reduces resource consumption by optimizing packaging levels, eliminating redundant packaging, and promoting the reuse of turnover barrels.
• Optimize the packaging level: A certain product originally used three-level packaging of "small box-medium box-large box". After optimization, the middle box was canceled and changed to "small box-large box" secondary packaging to reduce packaging materials. Innovate waste gas co-processing model to achieve synergistic effects of pollution reduction and carbon reduction.
Use.
During the reporting period, the Linping District ecological environment access waste gas co-processing pilot project promoted by the company was officially put into operation.
• Cancel redundant packaging: A certain material was originally packaged in cardboard drums. After evaluation, and on the premise of meeting quality requirements, cardboard drum packaging will be canceled from April 2025 to save packaging resources.
The project will connect the organic waste gas from the factory area to the adjacent ENN Energy natural gas boiler for collaborative incineration treatment to achieve reduction of
• Promote the reuse of turnover barrels: On the premise of meeting quality requirements, reusable turnover barrels are used as the outermost layer when transferring materials, and the PMC department will uniformly clean and label them.
Pollution reduction and carbon reduction are synergistic. The project has significant environmental benefits, saving more than 860 tons of standard coal every year and reducing CO₂
awareness and use management, and promote the recycling of packaging materials.
Emissions exceed 1,600 tons, and regional VOCs reduction exceeds 50%; economic benefits are outstanding, with annual natural gas consumption
〇 Quantitative indicators will drop from 101,700 cubic meters in 2022 to 0.1,800 cubic meters in 2024, RTO (Regenerative
Thermal Oxidizer (regenerative thermal incinerator) can save labor costs of 168,000 per year after being shut down.
Key Indicators Unit 2025
Yuan and maintenance cost 220,000 Yuan. The project has been awarded the Hangzhou Environmental Protection Demonstration Project and the 2023 Low Carbon Application
Packaging material consumption tons 234.60
Application scenarios and the second batch of pollution reduction and carbon reduction benchmark projects in Zhejiang Province. Packaging material consumption density of waste gas co-processing equipment tons/million revenue 0.06
37 38
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
〇 Quantitative indicators 〇 Quantitative indicators
Emissions Unit 2025 Emissions Unit 2025
Total exhaust gas emissions 10,000 cubic meters 21,450.05 Total hazardous waste emissions tons 1,506.00 Nitrogen oxide emissions tons 0.09 Hazardous wastes
Hazardous waste emission density tons/million revenue 0.42 Exhaust gas emissions Sulfur oxide emissions tons 0.02
Volatile organic compounds (VOCs) emissions tons 0.36 Total non-hazardous waste emissions tons 33.13 non-hazardous wastes
Particulate matter emissions tons 0.03
Non-hazardous waste emission density tons/million revenue 0.01
Wastewater Discharge Management
Noise management
The company's wastewater is mainly divided into industrial wastewater and domestic sewage, which comes from production workshops, R&D laboratories and office and living areas. The company strictly implements the separation of clean and sewage, diversion of rain and sewage, and separation of sewage and waste.
The company's noise mainly comes from the operation of production equipment, including fans, air compressors, vacuum pumps, crushers and central air-conditioning outdoor units. The company controls the source and blocks the flow of transmission, collects and processes all types of wastewater in categories, and establishes management mechanisms such as inspections of wastewater treatment facilities and regular monitoring of water quality to ensure that wastewater discharge meets standards.
Implement noise prevention and control measures at three levels: employee protection and employee protection to ensure that noise at factory boundaries meets standards.
• Industrial wastewater: After high-concentration wastewater is collected in a separate collection tank/trough, it is transported to the pretreatment system through overhead or open trench pipes to avoid mixing with general wastewater; after pretreatment, it is
• Source control: Prioritize the use of low-noise equipment; install sound insulation covers, shock-absorbing facilities and sound-absorbing materials for high-noise equipment.
The pretreated domestic sewage enters the regulating tank, is treated through the "aerobic-aerobic-sedimentation" process, and is finally discharged into pipes.
• Domestic sewage: combined with industrial wastewater after pretreatment. • Isolation of transmission paths: Optimize the layout of high-noise equipment and keep it away from sensitive areas; install soundproof windows and sound-absorbing materials in equipment rooms; install mufflers at the air inlets of fans.
• Initial rainwater: Initial rainwater in the production area is collected into the initial rainwater tank, and sent to the sewage station for treatment according to quality and quantity; clean rainwater is directly discharged. • Employee protection: Distribute noise protection equipment to employees and conduct regular noise monitoring at factory boundaries.
〇 Quantitative indicators
biodiversity
Emissions Unit 2025
Wastewater discharge 5 tons 57,105.40
Chemical oxygen demand (COD) tons 3.02 Betta Pharmaceuticals has incorporated biodiversity protection into its corporate environmental responsibility system and continues to improve the eco-friendly level of its operations. Wastewater discharge Ammonia nitrogen (NH3-N) discharge tons 0.27
Total nitrogen (TN) emissions tons 0.78
Total phosphorus (TP) emissions tons 0.01 As a pharmaceutical R&D and production enterprise, the company's operations do not involve the cultivation of medicinal materials or the direct mining of natural resources, and have a small direct impact on biodiversity. The company strictly abides by laws and regulations related to ecological protection and biodiversity, adheres to ecological priority in operations, ensures that waste gas, waste water, noise and solid waste meet the standards for discharge and compliant disposal, and minimizes production costs.
The impact of camping activities on the surrounding ecosystems, and implementation of biodiversity protection responsibilities with practical actions.
Solid Waste Discharge Management
The company's solid waste is divided into three categories: domestic waste, general industrial solid waste and hazardous waste, which come from offices, production workshops and R&D laboratories. The company follows reduction,
Based on the principles of resource utilization and harmlessness, a full-process management system for classified collection, standardized temporary storage, and compliant disposal has been established.
• Domestic waste and catering solid waste: Domestic waste and catering solid waste generated by the company are collected by the administrative department. Domestic waste is entrusted to the environmental sanitation department for removal, and catering solid waste is entrusted with a qualified certificate.
Bits are processed daily.
• General industrial solid waste: Temporary storage rooms are set up in the factory for classified storage, and disposal is entrusted to qualified units.
• Hazardous waste: Hazardous waste generated by the company's production operations mainly includes waste filtrate, waste solvent, waste activated carbon, waste packaging materials, waste medicine, sludge, etc., which are strictly in accordance with the National Hazardous Waste Regulations
Classify and collect hazardous waste according to the Catalog of Materials, use special containers and affix hazardous waste labels; the hazardous waste temporary storage warehouse is constructed according to standards and is anti-seepage, anti-corrosion, wind-proof, rain-proof, sun-proof and leak-proof.
The leakage collection function is entrusted to a unit holding a hazardous waste business license for disposal, a transfer slip system is implemented, and the ledger records are complete and archived for future reference. The company establishes a hazardous waste management plan
We will implement systems such as planning, declaration and registration, emergency plans and training drills, and conduct regular internal inspections to ensure that the entire process of hazardous waste from generation to disposal is compliant and controllable.
- The statistical scope of this environmental data covers industrial wastewater and domestic sewage generated during the company's operations.
39 40
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Bebe Dada Pharmaceutical Co., Ltd. || 22002255 Annual Cocoa Sustainable Development Development Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
employee hiring
Betta Pharmaceuticals strictly abides by the "Labor Law of the People's Republic of China", the "Labor Contract Law of the People's Republic of China" and the "Employment Promotion Law of the People's Republic of China", establishes an "Employee Handbook", builds a standardized and transparent employment system, and is committed to creating a fair, inclusive and healthy development environment for every employee, protecting legitimate rights and interests, and realizing employee and
The common growth of enterprises.
Standardize recruitment and employment
The company has established a standardized process system covering internal and external recruitment, and resolutely opposes child labor, discrimination and forced labor. It has clarified recruitment standards such as declaration of relatives and interests, background checks, and physical examinations. It has systematically established full-cycle management rules covering entry procedures, probation period assessments, regularization evaluations, attendance and holidays, salary and benefits, job changes, professional ethics, and resignation handovers, forming a recruitment and employment management system with clear rights and responsibilities, and orderly compliance.
Equal Employment Principles
key indicators
The company adheres to equal employment and eliminates any discrimination based on ethnicity, race, gender, religious belief, etc. Total number of employees
Provide employees with fair treatment and equal development opportunities regardless of any form of discrimination. In the recruitment circle
1,785
people
section, the company treats all job seekers equally and gives internal employees preferential treatment for vacant positions.
Compete for recruitment rights first to ensure fairness and inclusiveness in talent selection. in management appointments and
Percentage of women in senior management
In terms of employee promotion, the company strictly follows the criteria of ability, performance, quality and job suitability.
as the core basis, without setting differentiated standards based on gender, and ensuring that male and female employees enjoy equal 16.67%
People-oriented 04 level competition opportunities and development channels to ensure the balance and fairness of the promotion mechanism.
32 part-time employees, 6 senior managers, female employees
Work together 886 people
By employee type By employee level By gender
Full-time employees Middle management
Number of employees Number of employees Number of employees
1,753 people 427 people
899 male employees
1,352 ordinary employees
Contributing to SDGs, Betta Pharmaceuticals always adheres to the development philosophy of “people-oriented, working together” and insists on
Maintain occupational health and safety defense lines, optimize rights protection mechanisms, and expand talent development
long platform, build a warm and caring home, and strive to realize employees’ personal value and
Mutual achievements in the high-quality development of enterprises. 51 years old and above Hong Kong, Macao and Taiwan regions Overseas regions
58 people 0 people 13 people 30 years old and below
By age By region
466 people, 31-50 years old, mainland China
number of employees number of employees
1,261 people 1,772 people
41 42 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolence and mutual support
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
〇 Quantitative indicators Employee communication
Key Indicators Unit 2025
In order to further smoothen the communication channels between employees and management, and promptly collect and feedback employees’ questions, suggestions and demands, employees can communicate and interact with the company’s management through the following channels:
Employee turnover rate % 28.60
Male employees % 31.06
Attrition rate by gender. Induction training meeting for new employees and management. Communication between superiors and subordinates when employees become regular employees during probationary period. Employee performance interview activities. Female employees % 26.17-level interactive communication and interviews with the human resources department, etc.
30 years old and below % 39.06
Communication can be proposed in various types of work meetings. Various interactive communications organized by relevant departments. Employee representative meetings organized by trade unions, etc. The attrition rate is divided by age: 31-50 years old % 24.74
and exchange activities
51 years old and above % 15.00
The company occasionally holds symposiums and other communication and interactive activities between the chairman or senior executives and employees in mainland China % 28.82. Related questionnaire surveys implemented by the company, WeChat interactive activities carried out by the company’s official account, etc.
Churn rate by region Hong Kong, Macao and Taiwan % 0.00
Overseas areas % 0.00
Face-to-face symposium with Betta Pharmaceutical executives
The company effectively improves management through dialogue scenarios such as face-to-face meetings with senior executives and symposiums with outstanding employees.
Improve organizational transparency and employees' sense of belonging to achieve multiple values. At a strategic level,
Ability to obtain frontline feedback in a timely manner and dynamically adjust business direction; at the risk level,
Protection of employee rights and interests
Potential problems can be identified in advance and preventive mechanisms can be improved; at the same time, this measure also
Help create an open and inclusive organizational atmosphere, strengthen employer brand building, and further
Enhance the attraction of talents and fully stimulate the ownership spirit of employees so that everyone can
Betta Pharmaceuticals has always placed the protection of employees' rights and interests in an important position in corporate development. By building an equal and inclusive employment environment, smooth and efficient communication channels, and comprehensive and meticulous employees, they have become participants and promoters of the company's development. Senior executives have face-to-face group discussions on the on-site care system to effectively protect the legitimate rights and interests of employees.
Betta Pharmaceuticals held face-to-face symposium for employees
Diversity and Inclusion
Betta Pharmaceuticals has established a normal communication mechanism between senior management and employees, and regularly holds "face-to-face meetings with the chairman". By directly listening to frontline voices and responding to employees' concerns, communication is integrated into the full-cycle growth of employees.
The company strictly implements the relevant regulations on equal pay and equal employment to effectively protect the legitimate rights and interests of workers. In terms of employment of persons with disabilities, the company shall employ no less than 1.5% of the total number of employees.
ratio as a hiring benchmark to actively create inclusive employment opportunities. Job development follows the principle of "development according to needs, suitable for people and jobs", and systematically sets up jobs suitable for the physical and mental characteristics of persons with disabilities.
bits, such as online customer service, etc. The company continues to optimize the working environment. Facilities such as double-sided handrails on stairs, warning strips on the front of steps, barrier-free elevators and Braille signs are all in place to provide
Provide safe and accessible working conditions for employees with disabilities.
Employee communication and grievances
The company is committed to building an open and transparent communication culture. Through diversified dialogue channels and standardized complaint and reporting mechanisms, it ensures timely communication and effective response to employee demands, and continues to Excellent employee symposium - on-site communication between the chairman and employees Excellent employee symposium group photo to create an organizational atmosphere of mutual trust and win-win.
43 44
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Employee grievances Corporate culture construction
The company has established a standardized internal complaint and reporting channel to ensure that employee complaints are handled promptly and fairly. If employees encounter problems at work, they can first report them to their immediate superiors
The company has established a cultural work leading group headed by the CEO, which is fully responsible for the construction of corporate culture, systematically summarizes and refines the cultural connotation of Beida, and clearly reports with "Better"; if you are not satisfied with the results of the superiors' handling, you can submit a complaint to the Human Resources Department.
Medicine, Better Life" as its mission, "becoming a multinational pharmaceutical company headquartered in China" as its vision, and "hard work, innovative development, and value orientation" as its core values. At the same time, the company regards the Compliance Department as a specialized functional agency to accept reports of misconduct and is responsible for accepting reports of suspected violations of national laws and regulations or company rules and regulations. Based on this, a series of work concepts, team concepts, service concepts, talent concepts, etc. have been formed to jointly build a system with Betta characteristics and consistent with the company's sustainable development goals to ensure that relevant issues can be independently and compliantly investigated and handled. corporate culture system, and incorporate it into the important content of new employee induction training to promote publicity and implementation.
At the corporate culture level, the company has established 8 corporate culture clubs covering ball sports, outdoor sports, dance and other fields, covering more than 1,700 employees nationwide. The club carries out diverse themed activities every month to provide employees with physical and mental adjustment space, promote cross-departmental collaboration, and continue to promote the implementation and inheritance of corporate culture. It has been rated as Zhejiang Province, Employee Salary and Care, Hangzhou Civilized Unit and District-level Excellent Corporate Culture Club.
The company creates a warm workplace environment, effectively protects the rights and interests of employees through a complete salary incentive mechanism and comprehensive employee care, and creates a harmonious, warm and collaborative organization.
Atmosphere.
Employee compensation and benefits
The company pays five insurances and one fund for employees in accordance with the law, and fully implements statutory holidays such as paid annual leave, marriage leave, maternity leave, paternity leave, maternity leave, and breastfeeding leave. In terms of incentives, the company uses library tennis court
Diversified incentive methods, combining fixed salary with floating salary, and long-term and short-term incentives. By participating in market salary research, salary positioning is benchmarked against leading domestic and foreign pharmaceutical companies in the market.
Salary level to ensure that the company's salary level is market competitive.
In terms of floating salary, the company has established performance bonuses, project awards, and various types of evaluations. In terms of long-term incentives, the company implements equity incentive plans, and the incentive objects are not limited.
The equal bonus system combines company performance, department performance, individual performance and employee income with the company's middle and senior managers, and also provides professional and technical talents with outstanding performance and basic personnel with outstanding performance.
Closely linked, continue to increase incentives for outstanding performers, advocate the pursuit of excellence and include high-level employees, so as to promote the common growth of employees and the company. Table tennis court Basketball court
corporate culture.
Long-term service incentives: Establish "Loyal Service Award"
The company has established a "Loyal Service Award" to provide special recognition to core employees who have served for 5, 10, 15 and 20 years. Award custom-made "time hourglass" shaped trophy, which means time
Employee care
Witness loyalty.
The company continues to improve its employee care system, opens an internal employee canteen, and establishes a system "Canteen Food Safety Management System" to ensure the health of employees' meals.
Organize fun activities for Dragon Boat Festival and International Children’s Day
On the eve of the Dragon Boat Festival and International Children's Day in 2025, the company organized a "Children's Fun"
The themed activity of "Enjoy the Dragon Boat Festival with Zongzi" on June 1st includes dryland dragon boats, rolling hoops and making zongzi.
and other aspects to attract extensive participation from employees. The activities combine team competition and traditional folk customs
Combining experiences to enrich employees’ spare time cultural life and enhance team cohesion
To create a warm and harmonious holiday atmosphere. Zongzi making activity on site Dry land dragon boat activity on site On-site group photo of award-winning employees “Loyal Service Award” trophy
45 46 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolence and mutual support
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Employee training and development
Betta Pharmaceuticals’ “Eagle Series” Talent Training System
Betta Pharmaceuticals has built an "Eagle Series" talent training system covering the entire career cycle of employees:
The company believes that the growth of employees is the cornerstone of the company's sustainable development. Betta Pharmaceuticals continues to empower the company by building a systematic talent training mechanism and a deep integration platform of industry, academia and research.
• The Young Eagle Program is geared towards fresh graduates who have just entered Beida. It is carefully crafted in a more modern learning method, integrating online micro-courses, offline workshops, mentoring and teaching, to apply and practice the full-cycle growth of employees, and achieve the same frequency resonance between personal value and corporate innovation and development.
It is a comprehensive talent training program designed to help new graduates understand Beda, integrate into Beda, quickly become competent in their positions, and become outstanding individual contributors.
• The Flying Eagle Plan is specially designed for new managers. It focuses on new supervisors and the management pain points of new managers. It helps managers from the three perspectives of managing themselves, managing others, and managing business.
Employee training system
Master the basic concepts of management, understand roles, clarify functions, and realize the role transformation from individual contributor to team manager.
• The Eagle Plan faces outstanding managers and provides professional, stable and high-quality reserve management talents for business development. The Beida talent training system promotes "learning" by "learning" and focuses on the key behaviors of students in the project. It is centered on the construction of three core capabilities: leadership, professionalism and general knowledge. Among them, leadership development covers all levels of transition from new positions at the grassroots level to senior management, helping trainees improve their professional and management skills.
training; professional capacity building carries out targeted empowerment around major business sectors; general knowledge development is promoted through online learning, clubs and other forms; the system is based on rich courses
• The Jingying Plan focuses on managers at the director and deputy director levels, and cultivates leadership and management elites through the output of course cases such as managing self, managing others, and managing teams.
Program cases, a professional lecturer database and a convenient learning platform serve as the underlying support to ensure the efficient operation of the talent development system.
• The Leading Eagle program is specially designed for senior leaders. Through the Mini-MBA program, it helps senior executives broaden their understanding of overall business operations and improve their business sensitivity.
In order to cultivate more compound talents and achieve the talent training goals of innovation, practice and integration, the company launched the "Integration Plan" talent rotation training project. The project adheres to the "learning
"Understand deeply, integrate everything, apply what you learn, and advance with what you know and do", aiming to enrich work experience through job rotation in different positions. By the end of 2025, 10 employees have been included in the list
The plan.
〇 Quantitative indicators
Key Indicators Unit 2025
Male employees % 79.91
Female employees % 79.57Trained by gender and employee category
Senior management % 100% employees
Middle management % 85.61
Ordinary employees % 77.83
Male employee hours 37.01
Female employees Hours 36.85 By gender and employee category, each
Senior Management Hours 32.17 Average number of hours employees completed training
Middle Management Hours 41.34
Ordinary employee hours 35.59
Industry-university-research cooperation
Relying on the national postdoctoral research workstation, the company continues to deepen industry-university-research cooperation with well-known domestic universities, systematically introduces and cultivates high-level innovative talents, and provides solid support for corporate technological research and the transformation of scientific and technological achievements. In the process of talent training, the company has established a high-level tutor team composed of Betta national-level high-level talents and professor-level experts from well-known universities, with 26 internal and external tutors.
At the same time, Betta Pharmaceuticals adheres to the development concept of "integrating industry, academia and research, and jointly cultivating industry talents", and has joined forces with Shenyang Pharmaceutical University to jointly organize a master's degree upgrade program to encourage employees to obtain higher academic qualifications.
47 48
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Occupational Health and Production Safety The company has established a safety accident classification table to classify minor accidents, general accidents, major accidents and major accidents. Departments are graded on-site through monthly inspections and irregular spot checks, and responsibilities are divided between teams and individuals. In terms of rewards and punishments, financial penalties, termination of labor contracts, or downgrades will be imposed on those directly responsible, managers, and department heads based on the level of the accident. At the same time, joint measures such as deduction of department points and cancellation of reward qualifications will be established. As of the end of the reporting period, the signing rate of safety responsibility letters among various departments reached 100%, and no work-related injuries or deaths occurred among company employees.
By establishing and improving the occupational health and safety management system, Betta Pharmaceuticals continues to improve the safety production responsibility mechanism and systematically protects the occupational health and life safety of employees.
Security risk identification and prevention
Occupational health management
The company implements a monthly comprehensive inspection plan and carries out regular hidden danger inspections, establishes a safety hazard rectification list, promotes closed-loop safety management, and implements a safety responsibility assessment system. The company has established a score-based safety production inspection mechanism for low-risk departments in the assessment form. The assessment content covers the signing of responsibility letters, risk assessment, three-level training for new employees, and hidden dangers. The company has established and implemented 10 key links including the "Three Simultaneous" Management System for Occupational Health in Construction Projects, "Employee Occupational Health Monitoring and File Management System", "Occupational Disease Protection Facilities Maintenance, Inspection and Rectification, Safety Sign Management, System Implementation and Illegal Operations, Safety Facilities Effectiveness, Wearing Labor Protection Supplies, Emergency Drills, and Accident Handling." We will systematically promote occupational health and safety management through occupational health management system documents such as "Repair System" and "Responsibility System for Prevention and Control of Occupational Disease Hazards".
In 2025, the company received a total of 3 potential safety hazard inspections by regulatory agencies, namely the hidden danger inspection organized by the Linping District Emergency Management Bureau on May 27, and the Linping Economic and Technology Company strictly implemented the occupational health examination system covering the entire cycle in accordance with the law on July 24: The hidden danger investigation organized by the development zone and the hidden danger investigation organized by the Linping District Emergency Management Bureau on August 28 found 4, 6 and 9 hidden dangers respectively, totaling 19 items, all of which were general hidden dangers. The company has completed all rectifications on schedule in accordance with the rectification requirements of the regulatory agencies, with a rectification completion rate of 100%.
Pre-job physical examination On-the-job physical examination Off-the-job physical examination
Safety training
Employees who are engaged in operations exposed to occupational disease hazards must undergo occupational health examinations in July and August every year before leaving their jobs.
A physical examination must be completed before employment. The purpose is to discover employees with occupational bans and organize regular personnel physical examinations in accordance with national regulations, with the aim of clarifying the health status when leaving work and determining
To prevent unsuitable personnel from taking up the job, the public inspection fee will be paid to detect health damage early and establish personal liability. The company actively carries out safety production training. During the reporting period, the company carried out 11 safety production responsibility training, post-holiday resumption of work safety training, and pressure vessel safety training, all of which were undertaken by the company. Guardianship File. Covered 822 people. At the same time, we paid attention to contractor safety management and conducted 11 trainings for contractors during the reporting period to enhance their safety awareness.
On-site emergency response drill for nitrogen leakage in nitrogen equipment room
The company organized an on-site emergency response drill for nitrogen machine room leakage in June 2025. The drill simulated an inspection personnel being knocked unconscious due to a nitrogen leak and initiating a company-level Level II emergency response. A general headquarters was set up on site, with six professional teams including communication, emergency rescue, medical rescue, warning and evacuation, logistics support and news reporting.
Conduct practical simulations of rescue, blockage disposal, personnel treatment, on-site recovery and other processes.
The company actively carries out occupational health knowledge training
training, the training covers occupational hazards in this industry
hazard factors, occupational disease protection system, personal
Standard use of personal protective equipment and emergency response
Betta Pharmaceuticals obtained
Physician and health monitoring, etc., 2025
ISO 45001 Occupational Health and Safety Management System Certificate
A total of 209 people were covered throughout the year.
Emergency drill event site Emergency drill event host site
Safety production management
〇 Quantitative indicators
The company implements the policy of "safety first, prevention first", establishes and improves a safe production management mechanism covering all levels and positions, and uses institutionalized and standardized measures to ensure the safety of employees.
life safety and stable business operations.
Key Indicators Unit 2025
Number of work-related deaths: 0
safety management system
Number and rate of work-related deaths
Proportion of work-related fatalities % 0 The company has established a safety responsibility system with the "Safety Production Responsibility System" as the core, and established a safety responsibility assessment based on safety accident classification and department risk classification.
The number of working days lost due to work-related injuries is 0 days.
49 50
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Bebe Dada Pharmaceutical Co., Ltd. || 22002255 Annual Cocoa Sustainable Development Development Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Public welfare party building
Betta Pharmaceuticals actively fulfills its social responsibilities, practices patient assistance and student care, delivers warmth and lights up hope through diversified public welfare practices, and continues to promote the harmonious symbiosis between the enterprise and society.
In 2025, the company will continue to deepen the "connecting villages and villages" and implement the plan for students from needy families in Yuhang District, Hangzhou City
pairing assistance work, providing financial support and moral encouragement to guide them to study seriously and actively progress
Take; the company donated hundreds of thousands of yuan to the Beijing Science and Technology Innovation Medical Development Foundation to give back to the society with public welfare.
Fulfill social responsibility. Mr. Ding Lieming participated in the Environment and Health Publicity Week and "Zhejiang Love Wuhen·Hang Xiangtong"
"Exercise" large-scale activities, covering first aid skills training (cardiopulmonary resuscitation/AED practical), disease prevention and treatment department
We provide core links such as general education and health consultation, focus on people’s health and well-being, carry out diversified services, and pool resources.
Source donated free HPV bivalent vaccine and 300 copies of "Health Guide" worth 18,000 yuan to benefit
More than 200 people attended the event, further deepening the brand building of "Zhejiang Love Wuhen" and promoting a healthy China
Publicity on “Environmental and Health Awareness Week”
Contribute to construction and common prosperity.
The Party Committee of Betta Pharmaceuticals is guided by Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, adheres to the work theme of "Party building gathers talents, and talents lead innovation", and promotes high-quality development of the enterprise with high-quality party building. The Party Committee carries out theoretical study and policy interpretation on a regular basis, holds national publicity meetings for the spirit of the Two Sessions, organizes viewing activities for the "93 Military Parade", deepens the study and rectification of the spirit of the eight central regulations, and creates a clean and upright environment; fully ensures that representative members can make suggestions and suggestions, and representatives of the 20th National Congress of the Party and other representatives can participate in political discussions and publicity activities, and fulfill corporate political and social responsibilities ; Continue to consolidate the organizational foundation, optimize team building, standardize development, and improve management efficiency; enrich activity carriers, go to Tonglu to carry out "July 1" activities such as red education and knowledge competitions, and enhance the cohesion of the party organization; establish a good party building position, receive 17 external surveys throughout the year, actively undertake municipal-level theme activities, and set up an on-site teaching point for theoretical traceability in Hangzhou. As a member of the National Committee of the Chinese People's Political Consultative Conference, Mr. Ding Lieming immediately went to the Zhejiang Overseas Chinese Federation, the Provincial and Municipal Federation of Industry and Commerce at all levels, the Hangzhou Bureau of Veteran Cadres, and the Linping District Committee and District Government to interpret the spirit of the two sessions after the National Two Sessions, and preached on the development of new productive forces according to local conditions, the development environment and opportunities of the innovative pharmaceutical industry, technological innovation and industry A series of new spirits such as innovation and deep integration not only empower the high-quality development of the local economy, but also publicize the new achievements made by the government in unswervingly consolidating and expanding the results of poverty alleviation. It also promotes the new deployment of rural revitalization in the government work report and guides all walks of life to further unify thoughts and actions into the decision-making and deployment of the Party Central Committee.
Helping each other with kindness 05
patient assistance
Good deeds go a long way
In 2025, the company's assistance projects will benefit 180,000 patients with lung cancer and renal cell cancer, with a total of 750,000 boxes of free medicine, and an investment of approximately 750 million yuan in inclusive medical care.
Mena Xinsheng-Patient Assistance Platform
The company and the China Pharmaceutical Innovation Promotion Association jointly launched a post-marketing clinical application observation and re-evaluation project.
Contributing to SDGs Betta Pharmaceuticals actively fulfills its social responsibilities and practices patient assistance and charity. There are no restrictions on regional quotas, economic conditions and other priority terms. The platform builds a full-cycle follow-up care service
System, service satisfaction reaches 100%. The company has carried out in-depth cooperation with 620 pharmacies across the country to improve the flow of assistance.
Deliver warmth and hope with practical actions and continue to promote harmony between enterprises and society
The collaborative efficiency of the process and patient management has effectively alleviated the financial pressure on patients’ families. This project has been running since 2011
Symbiosis.
Since it started operation in July, it has benefited more than 150,000 patients with lung cancer and renal cell carcinoma, and won the third China National Cancer Award.
China Philanthropy Festival’s “China Philanthropy Practice Award” and the fifth and sixth China Philanthropy Festival’s “Responsible Brand Award”.
〇 Quantitative indicators
Key Indicators Unit 2025
Amount of public welfare donation 10,000 yuan 193.07 Duration of public welfare investment hours 160
51 52
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Appendix Key Indicators Unit 2023 2024 2025
Purchased electricity kWh 17,487,770.00 13,286,000.00 17,716,810.00
Purchased steam tons 5,393.85 4,760.18 5,978.65
Greenhouse gas emissions1
Appendix I Key Performance Table
Scope 1 greenhouse gas emissions tons of carbon dioxide equivalent 2,282.73 2,023.91 1,267.74
Scope 1 greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 0.93 0.70 0.35
Key indicator Unit 2023 2024 2025 Scope 2 greenhouse gas emissions tons of carbon dioxide equivalent 10,876.99 8,459.80 11,171.77 Number of completed corruption litigation cases 0 0 0 Scope 2 greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 4.43 2.93 3.10 Scope 3 greenhouse gas emissions tons of carbon dioxide equivalent 121,112.90 114,778.61 151,301.66 Total number of directors participating in anti-corruption training Person 5 5 6
Scope 3 Category 1 - Outsourced goods and services tons of carbon dioxide equivalent 118,103.64 110,744.50 147,467.04 Average number of hours directors participated in anti-corruption training hours 1 1 2
Anti-corruption training
Scope 3 Category 5 - Waste generated during operations Ton of carbon dioxide equivalent 1,520.40 2,674.74 2,524.16 Total number of employees participating in anti-corruption training Person-time 3,359 2,968 3,169
Scope 3 Category 7 - Employee Commuting Ton of carbon dioxide equivalent 1,488.86 1,359.37 1,310.46 Average total training hours for employees to participate in anti-corruption training Hours 1.35 0.76 1.08
Scope 3 greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 49.31 39.69 41.92
environment
Total greenhouse gas emissions tons of carbon dioxide equivalent 134,272.62 125,262.32 163,741.17 Emissions
Greenhouse gas emission density tons of carbon dioxide equivalent/million revenue 54.67 43.31 45.37 Total waste gas emissions 10,000 cubic meters 18,120.54 17,104.76 21,450.05
Society
Nitrogen oxide emissions tons 0.0001 0.16 0.09
employee hiring
Exhaust gas emissions Sulfur oxide emissions tons 0.03 0.02 0.02
Total number of employees 1,936 1,696 1,785Volatile organic compounds (VOCs) emissions tons 1.17 0.24 0.36
By employee type Full-time employees Person 1,903 1,669 1,753 Particulate emissions tons 0.06 0.03 0.03
divided employees
Wastewater discharge tons 84,836.63 72,656.81 57,105.40 Number of part-time employees Person 33 27 32 Chemical oxygen demand (COD) tons 3.09 3.03 3.02 Senior management Person 6 5 6By employee level
Wastewater discharge Ammonia nitrogen (NH3-N) discharge tons 0.06 0.13 0.27 Employees divided Middle management Person 380 374 427 Number of people
Total nitrogen (TN) emissions tons 0.60 0.45 0.78 Ordinary employees Person 1,550 1,317 1,352 Total phosphorus (TP) emissions tons / 0.02 0.01 By gender Male employees Person 928 832 Number of employees of 899 Female employees Person 1,008 864 886Total hazardous waste emissions Ton 889.48 1,321.70 1,506.00
hazardous waste
Proportion of women in senior management % 16.67% 20.00% 16.67% Hazardous waste emission density tons/million revenue 0.36 0.46 0.42
Persons aged 30 and under 451 415 466 Total amount of non-hazardous waste discharge tons 40.21 41.64 33.13
Non-hazardous waste by age
31-50 years old People 1,403 1,220 1,261Non-hazardous waste emission density tons/million revenue 0.02 0.01 0.01 Number of employees
People aged 51 and above 82 61 58 Water usage
Mainland China People 1,919 1,683 1,772 Water consumption cubic meters 258,954.00 276,035.00 231,406.00
by region
Hong Kong, Macao and Taiwan People 0 0 0 Water consumption density Cubic meters/million revenue 105.43 95.45 64.11 Number of employees
Overseas regions People 17 13 13 Packaging material usage
Employee turnover rate % 25.40 38.00 28.60 Packaging material consumption tons 192.85 202.77 234.60
Packaging material consumption density tons/million revenue 0.08 0.07 0.06 By gender Male employees % 26.95 38.75 31.06 Turnover rate Female employees % 23.96 37.29 26.17Energy
30 years old and below % 38.80 56.39 39.06 Comprehensive energy consumption tons of standard coal 3,537.10 2,863.57 2,946.88 By age
31-50 years old % 20.79 33.08 24.74 Churn rate
Comprehensive energy consumption intensity tons of standard coal/million revenue 1.44 0.99 0.82
51 years old and above % 28.89 30.56 15.00Diesel consumption Liter 320.20 420.76 1,332.67
Mainland China % 25.62 38.31 28.82 Gasoline consumption (for business travel) Rise 4,408.06 2,896.73 6,227.56 By region Hong Kong, Macao and Taiwan % 0.00 0.00 0.00Loss rate
Natural gas consumption cubic meters 1,039,272.00 922,300.00 571,887.00 Overseas regions % 0.00 0.00 0.00
- Source of emission factor: "Announcement on the Release of Electricity Carbon Dioxide Emission Factor in 2023" issued by the Ministry of Ecology and Environment of the People's Republic of China. The national average carbon dioxide emission factor for electric power in 2023 is 0.5306 kg of carbon dioxide/kWh.
53 54 Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Key Indicators Unit 2023 2024 2025 Appendix II ESG Guidelines Index of Shenzhen Stock Exchange and Hong Kong Stock Exchange
staff training
Male employees % 76.72 77.44 79.91 Shenzhen Stock Exchange’s "Self-discipline Supervision Guidelines for Listed Companies No. 17 - Sustainability Reporting (Trial)" index table Female employees % 79.74 78.69 79.57
% of trained employees by gender Senior management % 100 100 100
Dimension Serial Number Topic Corresponding Clause Report Chapter
Middle management % 82.76 85.14 85.61
1 Coping with climate change Articles 21 to 28 Low-carbon operations, green escort—coping with climate change Ordinary employees % 77.33 76.31 77.83
Male employee hours 40.99 32.51 37.01
2 Pollutant Emissions Article 30 Low-carbon Operation, Green Escort—Female Employees in Emission Management Hours 36.78 30.26 36.85
By gender and employee category, each employee
Senior Management Hours 31.33 28.48 32.17
Average hours of training completed 3 Waste Disposal Article 31 Low-carbon operation, green escort—emissions management middle management hours 26.76 22.31 41.34
Ordinary employee hours 41.72 33.89 35.59 4 Ecosystem and biodiversity protection Article 32 Low-carbon operation, green protection—biodiversity occupational health and safety Environment
5 Environmental Compliance Management Article 33 Low-carbon Operation, Green Protection—Environmental Management People who died due to work-related deaths in the past three years Number of work-related deaths Person 0 1 0
Number and ratio Ratio of work-related fatalities % 0 0.059 0
6 Energy Utilization Article 35 Low-carbon operation, green protection—Energy usage Number of working days lost due to work-related injuries Days 0 0 0
Charity
7 Water Utilization Article 36 Low-carbon Operation, Green Protection—Resource Management Public Welfare Donation Amount 10,000 yuan 232.48 199.36 193.07
Length of public welfare investment Hours 213 376 160 8 Circular Economy Article 37 Low-carbon operation, green escort—resource management R&D and innovation
9 Rural Revitalization Article 39: Together with benevolence, good deeds will go a long way—Public charity R&D investment 10,000 yuan 100,205.05 71,717.78 57,350.02
R&D investment as a proportion of operating income % 40.80 24.80 15.89
10 Social Contribution Article 40: Working together with benevolence and doing good deeds for a long time—Public welfare and charity R&D personnel Person 562 327 298
Proportion of R&D personnel % 29.03 20.07 16.69 11 Innovation-driven Article 42 Quality-oriented, protecting health - R&D and innovation registered trademark items 373 375 376
Registered patent items 163 207 238 12 Science and technology ethics Article 43: Quality first, protecting health—clinical trials and subject safety work copyright items 9 9 9
13 Supply Chain Security Article 45: Quality First, Protect Health—Sustainable Supply Chain Registration Domain Name Item 3 3 2 Society
Software copyright items 10 10 10
14 Treat small and medium-sized enterprises equally Article 46: Put quality first and protect health—Number of invention patent applications for sustainable supply chain 117 69 39
Number of invention patents authorized 28 46 29 15 Safety and quality of products and services Article 47: Quality-oriented, protecting health—number of valid patents on product quality and safety 175 215 237
Invention patent items applied to main business 174 213 235 16 Data security and customer privacy protection Article 48 Quality-oriented, protecting health—Privacy protection and information security Product quality and safety
People-oriented, working together - employee employment, employee rights protection, safety reasons among the total number of products sold or shipped 17 Employees Article 50
% 0 0 0 Occupational Safety and Health
Percentage of recycling for health reasons
Number of product and service complaints 7 10 7
18 Due Diligence Article 52 Steady Quality, Trustworthy Management—Risk Compliance Management Complaint Handling Rate % 100 100 100
Sustainable Supply Chain 19 Stakeholder Communication Article 53 Steady Quality, Trustworthy Management—ESG Governance for Sustainable Development
Total number of suppliers 1,835 1,712 1,695
Related governance
Mainland China Home 1,695 1,571 1,528 20 Anti-commercial bribery and anti-corruption Article 55 Steady quality, trustworthy management - Business ethics and anti-corruption Hong Kong, Macao and Taiwan Home 3 1 3
21 Anti-unfair competition Article 56 Steady quality and trustworthy management—Business ethics and anti-corruption Overseas regions Home 137 140 164
55 56
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Hong Kong Stock Exchange's "Environmental, Social and Governance Reporting Guide" Index Table Main Scope, Aspects, General Disclosures and Key Performance Indicators Relevant sections or other explanations of this report
B. Society
Main scope, levels, general disclosures and key performance indicators Relevant chapters or other explanations of this report Employment and labor practices
A. Environmental General Disclosures
Regarding providing a safe working environment and protecting employees from occupational hazards:
General Disclosure People First, Working Together - Occupational Health and Safety
(a) policy; and
Regarding waste gas emissions, discharge of pollutants to water and land, generation of hazardous and non-hazardous waste, etc.:
(b) Information on compliance with relevant laws and regulations that have a significant impact on the issuer.
(a) Policy; and B2:
Low-carbon operation, green escort—emissions management
health and safety
(b) Information on compliance with relevant laws and regulations that have a significant impact on the issuer. B2.1 The number and rate of work-related fatalities in each of the past three years (including the reporting year) People-oriented, working together - Occupational health and safety Note: Exhaust gas emissions include nitrogen oxides, sulfur oxides and other substances regulated by national laws and regulations
contaminants. Hazardous waste refers to those defined by national regulations. B2.2 Number of working days lost due to work-related injuries People-oriented, working together - Occupational health and safety A1.1 Types of emissions and related emission data Low-carbon operations, green escort - Emissions management B2.3 Describe the occupational health and safety measures adopted, and related implementation and monitoring methods. People First, Working Together—Occupational Health and Safety A1: A1.2 [Deleted on January 1, 2025] / General Disclosure
Emissions
Policies on improving employees' knowledge and skills in performing their job responsibilities. Describe training activities. People-oriented, working together - employee development and training A1.3 Total amount of hazardous waste generated (in tons) and (if applicable) density (e.g. per unit of production)
Unit of measurement, calculated for each facility) Low-carbon operation, green escort—emissions management Note: Training refers to vocational training, which can include internal and external courses paid for by the employer.
B3:
A1.4 Total amount of non-hazardous waste generated (in tonnes) and (if applicable) density (e.g. per unit of production) Development and Training B3.1 Trained employees by gender and employee category (e.g. senior management, middle management)
Low-carbon operation, green protection—emissions management, people-oriented, working together—employee development and training volume unit, calculated per facility) percentage.
A1.5 Describe the emission targets set and the steps taken to achieve these targets. Low-carbon operations, green escort - emission management B3.2 The average number of training hours completed by each employee by gender and employee category. People-oriented, working together - employee development and training A1.6 Describe the methods of handling hazardous and non-hazardous waste, and describe the waste reduction goals and general disclosures
Low-carbon operation, green escort—emissions management
steps taken to achieve these goals
Regarding the prevention of child labor or forced labor:
People-oriented, working together - General disclosure on employee rights protection (a) policy; and
B4:
Policies for the efficient use of resources, including energy, water and other raw materials. Low-carbon operation, green protection—energy use, resource management (b) Information on compliance with relevant laws and provisions that have a significant impact on the issuer.
Labor Code
Note: Resources can be used for production, storage, transportation, buildings, electronic equipment, etc.
B4.1 Describe measures to review recruitment practices to avoid child labor and forced labor. People-oriented, working together - Protection of employee rights and interests A2.1 Total direct and/or indirect energy (such as electricity, gas or oil) consumption by type (in thousands
Calculated per kilowatt-hour) and density (e.g. calculated per unit of output, per facility) Low-carbon operations, green protection—energy use B4.2 Describe the steps taken to eliminate violations when violations are discovered. People-oriented, working together - employee rights and interests protection A2: A2.2 Total water consumption and density (e.g. calculated per unit of production, per facility) Low-carbon operation, green escort - Resource management General disclosure
Resource use, quality first, health protection—sustainable supply chain
Policies for managing environmental and social risks in supply chains.
A2.3 Describe the energy efficiency goals set and the steps taken to achieve these goals Low-carbon operation, green protection—energy use
B5.1 Number of suppliers by region Quality-oriented, healthy-sustainable supply chain A2.4 Describe any problems in obtaining suitable water sources, as well as the water efficiency targets set and
Low-carbon operation, green escort—resource management
steps taken to achieve these goals
B5: B5.2 Describe the practices for engaging suppliers, the number of suppliers to whom the practices are implemented, Quality-oriented, Healthy - Sustainable Supply Chain A2.5 The total amount of packaging materials used in finished products (in tons) and (if applicable) per production unit Supply chain management and related implementation and monitoring methods.
Low-carbon operation, green escort—resource management
Occupy
B5.3 Describe practices for identifying environmental and social risks at each stage of the supply chain, and related
Quality first, health protection—sustainable supply chain
Implementation and monitoring methods.
General disclosure
Low-carbon operation, green protection—biodiversity
A3: Policy to reduce the issuer's significant impact on the environment and natural resources B5.4 Describe the practices to promote the use of more environmentally friendly products and services when selecting suppliers, and related implementation
Environment and nature, quality first, health protection—sustainable supply chain
Implementation and monitoring methods.
Gas Resources A3.1 Describe the significant impacts of business activities on the environment and natural resources and the measures taken to manage the relevant impacts
Low-carbon operation, green protection—biodiversity
action. General disclosure
B. Social Health and Safety, Advertising, Labeling and Privacy Matters and Remedies Regarding Products and Services Offered
Quality first, protecting health - privacy protection and information security,
method:
Employment and Labor Practices (a) Policies; and Product Quality and Safety
(b) Information on compliance with relevant laws and regulations that have a significant impact on the issuer.
General disclosure
Regarding pay and dismissal, recruitment and promotion, working hours, holidays, equal opportunities, diversity,
People-oriented, working together - employee employment, employee rights and interests B6: B6.1 Percentage of the total number of products sold or shipped that must be recalled for safety and health reasons. Quality first, protecting health - product quality and safety, anti-discrimination and other treatment and benefits:
product liability
protect
(a) Policy; and B6.2 Number of complaints received about products and services and methods of response. Quality first, protecting health—product quality and safety B1:
(b) Information on compliance with relevant laws and regulations that have a significant impact on the issuer.
Employment B6.3 Describe practices related to maintaining and protecting intellectual property rights. Quality First, Protecting Health—Intellectual Property Protection B1.1 Employees by gender, employment type (such as full-time or part-time), age group and region
Total Diversity and Equal Employment People-oriented, Hand in Hand - Employee Employment B6.4 Describe the quality inspection process and product recycling procedures. Quality-oriented, protecting health—product quality and safety
B1.2 Employee turnover rate by gender, age group and region People-oriented, working together - employee employment B6.5 Describe the consumer data protection and privacy policy, and related implementation and monitoring methods. Quality first, protecting health—privacy protection and information security
57 58
Steady governance, quality-oriented, low-carbon operation, people-oriented, benevolent and cooperative
Betta Pharmaceutical Co., Ltd. | 2025 Sustainability Report
Trustworthy management, protecting health, green escort, working together to achieve long-term good deeds
Main scope, level, general disclosure and key performance indicators Relevant chapters or other explanations of this report Appendix III Feedback Form B. Society
Employment and Labor Practices Dear Reader:
Hello! Thank you for taking the time to read our report. We look forward to sharing any opinions and ideas about the report to help us continue to improve our report preparation methods and general social responsibility disclosures.
job performance.
Regarding the prevention of bribery, extortion, fraud and money laundering:
Steady governance, trustworthy management - business ethics and anti-corruption
(a) policy; and
(b) Information on compliance with relevant laws and regulations that have a significant impact on the issuer.
Which of the following stakeholders best describes who you are?
B7：
Anti-corruption
B7.1 Number of concluded corruption lawsuits filed against the issuer or its employees during the reporting period
Steady governance, trustworthy management - business ethics and anti-corruption
and the outcome of litigation.
□Government/regulatory agencies □Suppliers □Investors and shareholders B7.2 Describe preventive measures and reporting procedures, as well as related implementation and monitoring methods. Steady governance, trustworthy management - business ethics and anti-corruption
□Employees □Distributors □Environmental organizations B7.3 Describe anti-corruption training provided to directors and employees. Steady governance, trustworthy management - business ethics and anti-corruption
□Patients/Clients □Community Public □Others (please specify) General Disclosure
Regarding using community participation to understand the needs of the community where it operates and ensuring that its business activities will consider the community, be kind and help each other, and do good deeds for a long time-Public charity
interest policy.
B8：
community investment
B8.1 Focus on contribution areas (such as education, environmental issues, labor needs, health, culture, sports). Working together with benevolence, good deeds go a long way—Public charity What do you think of this report:
B8.2 Resources (such as money or time) used in the area of focus. Be benevolent and help each other, good deeds will go a long way - public welfare and charity
D. Climate-related disclosures Evaluation dimensions Very good Better Average Poor Very poor
Report structure
Information about the governance bodies or individuals responsible for overseeing climate-related risks and opportunities, including how technology is identified
Governance Competencies, frequency of learning about risks and opportunities, how to consider them in decision-making, and supervision of target systems. Green escort of low-carbon operations-responding to climate change-governance. Information disclosure and compliance progress, as well as the role of management in relevant processes and integration with internal functions. Layout design.
Readability
Describe the current and expected impacts of climate-related risk opportunities on the business model and value chain, identifying
Overall rating
Central region; disclose strategies and plans to deal with risk opportunities, including business model changes, adaptation or
Strategy Mitigation efforts, transition plans, ways to achieve climate goals, and resource provision plans for action Low Carbon Operations Green Escort - Addressing Climate Change - Strategy
and progress of previous plans; disclosing the impact of climate-related risks and opportunities on the issuer’s financial position during the reporting period
current and expected financial impact on our financial condition, financial performance and cash flows
Which chapter best meets your needs? (optional 2 items)
Disclosures are used to identify, assess, prioritize and protect climate-related risks and opportunities.
Low-carbon operation green escort-coping with climate change-impact, wind
Risk Management Maintains monitoring of processes and related policies, and integrates climate-related risks and opportunities into the company's overall risks
risk and opportunity management
□Chairman's speech □Steady governance, trustworthy management □Low carbon operation, green escort management process
□About us □Quality-oriented, protecting health □People-oriented, working together to make progress
Disclose the absolute total emissions of Scope 1, Scope 2 and Scope 3 greenhouse gases during the reporting period, and explain the measurement
Methodology, inputs, assumptions and reasons for changes, disclosure of Scope 2 emissions on a geographical basis and Scope 3
Contains categories. Disclose climate-related qualitative and quantitative goals, including setting indicators, goals, and applications. Low-carbon operation green escort-responding to climate change-indicators and
Indicators and targets
Goal Do you have any other comments or suggestions about our sustainability report or responsibility performance? Scope, period, base period, milestones, target types, association with international agreements; disclosures
Set audit target methods, monitor compliance progress indicators, target performance and trend analysis; for greenhouses, you can give us feedback through Betta Pharma’s email address ([email protected]). Gas emission targets, describing the gases covered, emission scope, total or net targets, etc.
59 60